Header Image
Psychiatric comorbidities in ADHD

Psychiatric comorbidities in ADHD

Author: Ulrich Brennecke
Review 10/2024: Dipl.-Psych. Waldemar Zdero

In persons with ADHD, the following psychiatric disorders often occur in addition (comorbid), sorted in descending order of frequency with ADHD (in % of people with ADHD) compared to the frequency in non-affected persons.

Adults with the highest 10% of ADHD symptom severity according to ADHD-E were 6.99 times more likely to experience psychological distress than non-affected adults.1

One study found 51.8% of people with ADHD had one or more comorbid mental illnesses.2
Another study in Japan in 2019 found comorbid ASD in 54.4% of children and adolescents with ADHD and affective disorders (depression, etc.) in 60.9% of adults.3

The percentages in the headings should indicate the frequency of comorbidity in ADHD. Example: 70 to 80 % of children with ADHD suffer from sleep disorders, compared to 35 to 40 % of children without ADHD. Unfortunately, the figures are currently mixed up and need to be corrected.

1. Learning disorders - up to 92

1.1. Learning disorders in children - 10 to 92 %

10 - 92 % Frequency of comorbidity in children with ADHD4/ general learning disability (approx. 20 %)56

1.2. Learning disorder in adults - 2 % (vs. 1.6 %)

Total adults 1.6 %; women 1.4 %, men 2.4 %; ADHD-I 1.5 %, ADHD-C 2.5 %, ADHD-HI 2.5 %7

2. Autism Spectrum Disorders (ASD) - 3.6% to 85% (vs. 0.40% for girls to 1.85% for boys)

People with ADHD have a high risk of comorbid ASD.

  • 15- to 21-fold risk (based on an ASA population prevalence of 1%)(meta-analysis)8
    • 15% to 21% of children and adolescents with ADHD have an autism spectrum disorder
    • Children with ADHD with ASD show stronger ADHD symptoms than children without ADHD
  • 24% of children with ADHD met the criteria for ASD9
  • 31% to 37% increased risk of ASA10

Children with ADHD without an ASD diagnosis showed increased ASD traits11, which was associated with negative interpersonal, academic and cognitive outcomes12.
The degree of autistic characteristics in children without ASD can be measured using the CBCL-AT scale.1314 The CBCL-AT scale is positive if the sum of the T-scores for the withdrawal, social problems and thinking problems subscales of the Child Behavior Checklist (CBCL) is 195 or greater. According to this criterion, 18.18% of children with ADHD without autism showed autistic traits, compared to 0.87% of children without ADHD (20.9-fold risk, + 1,990%).14

  • 60% of children with ADHD showed ASD traits.1516

People with ADHD also have an increased risk of ADHD617 18 19 It has been named with:

  • 85 %20
  • 78 % (among n = 83 children with ASD, Asperger’s and permanent developmental disorder)21
  • 26 % (study of n = 103 children, 85 % of whom were boys with ADHD without intellectual impairment - 27 cases were found to have previously undiagnosed ASD)22
  • 21.6% of people with ADHD had comorbid ADHD23
  • 3.6 % over the entire age range (cohort study)24

DSM-IV still stipulated that ADHD and autism spectrum disorders should not be diagnosed as comorbid. This was changed in DSM 5.

Girls with autism who also had ADHD showed significantly stronger symptoms of ADHD, learning disabilities and ODD than boys with ASD and ADHD in a large study.25

In the overall population, ASD occurs in 1 in 54 boys (1.85%) and 1 in 252 girls (0.40%).26

There is evidence that ADHD and autism have common genetic roots.2710 ADHD and ASD share two genes known as risk genes.17 There are suggestions that ADHD and autism may have further common genetic roots.27 Disorders of dopaminergic neurotransmission are suspected in ASD, among other things,28 while such disorders are documented in ADHD.

Around 28%29 to 50% of people with ADHD have ADHD as a comorbidity.
The fact that ADHD could not be diagnosed in autism according to DSM IV speaks against empirical experience and is therefore omitted in DSM 5.18

3. Sleep disorders - up to 80

3.1. Sleep disorders in children with ADHD - 70 to 80 % (vs. 35 to 40 % = + 100 %)

70 - 80 %30; 73.3 % (28.5 % mild plus 44.8 % moderate and severe),316 twice as common as in children not affected by the disease3233
For the treatment of sleep disorders Sleep problems with ADHD.

A meta-analysis found that around 33% of people with narcolepsy also have ADHD.34
Narcolepsy is associated with a reduced level of dopamine in the cerebrospinal fluid. This is consistent with the dopamine deficiency found in ADHD. In dogs with narcolepsy, on the other hand, increased dopamine levels were found in the amygdala and increased noradrenaline levels in the oral pontine reticular nucleus. Nevertheless, the dogs respond to stimulants that increase dopamine and noradrenaline.35
Kooij sees sleep disorders (difficulty falling asleep or sleeping through the night) in 43% of people with ADHD.36

3.2. Sleep disorders in adults with ADHD - 11.3% (vs. 2.3%)

Sleep problems that last longer than a month are called sleep disorders.

  • In adult people with ADHD: 11.3%37 to 29%38
  • For non-affected persons: 2.3 %37
    = 5 to 12 times the risk

The annual prevalence of sleep disorders in Germany in 2008 was 0.6 % (15 to 19 years) to 6.6 % (60 years and over) for men and 0.8 % (15 to 19 years) to 7.8 % (60 years and over) for women.39
Sleep problems with ADHD are extremely common:

  • 70 - 80 % of people with ADHD suffer from sleep problems
  • 20 - 30 % of adults with ADHD suffer from sleep problems
    Of the 670 adult persons with ADHD (with a medical diagnosis) who took the ADxS.org online symptom test, 69% reported sleep disorders, compared to 39% of the 159 people with ADHD who said they were certainly not affected (as of March 1, 2022).

A meta-analysis found that around 33% of people with narcolepsy also had ADHD.34

3.3. Consequences of sleep disorders (sleep disorders: children 47.1 %; adults: 0.6 to 7.8 %)

A Chinese study of 23,791 schoolchildren found that 68.7% of children with ADHD had poor sleep quality, compared to 47.1% of children without ADHD40

See also: ADHD - comorbidity, there on sleep problems

When it comes to sleep problems and ADHD, it is difficult to separate cause and effect. ADHD very often causes sleep disorders and sleep disorders often cause ADHD-like symptoms.

In the case of an ADHD diagnosis, comorbid sleep disorders should always be treated with special priority. In addition, when taking medication for sleep problems, their possible negative effect on ADHD symptoms must be taken into account, just as medication for ADHD must be checked to ensure that it does not exacerbate sleep problems. More on the treatment of sleep problems with ADHD: Treatment of sleep problems with ADHD

  • Vigilance disorders with impaired sleep-wake regulation4142
  • Consequences of sleep apnea syndrome43
    Obstructive sleep apnoea syndrome (OSAS) is the most common sleep-related breathing disorder. The prevalence is around 4% in men and around 2% in women.
    Obstructive sleep apnea (OSA) is even more common and reaches strikingly high figures, particularly when subgroups are considered. For example, there is a prevalence of around 36% in patients with diabetes mellitus or arterial hypertension, a prevalence of 50% in obese patients and a prevalence of 83% in patients with refractory arterial hypertension. It is estimated that 80 % of male and 90 % of female patients with sleep apnoea syndrome are undiagnosed and therefore untreated.”44
    Breathing interruptions in children’s sleep can trigger cognitive stress, causing symptoms that resemble ADHD.45
  • Chronic lack of sleep41
  • Disorders of the dream sleep phases occur within a few days:
    • Increased irritability46
    • Increased impulsivity46
    • Reduced concentration47
    • Reduced attention47
    • Disorders of the working memory48

Common symptoms of sleep problems and ADHD:49

  • Motor hyperactivity, physical restlessness
  • Concentration problems
  • Attention problems

ADHD symptoms that are atypical of sleep problems:

  • Inner restlessness (typical in atypical depression, less so in melancholic depression)
  • Impulsiveness
  • High flow of speech (logorrhea, polyphrasia)
  • Chasing thoughts, circling thoughts
  • Rapid mood swings
  • Dysphoria with inactivity

Symptoms of sleep problems that are atypical for ADHD:

  • Drowsiness
  • (Day) tiredness

4. Body-related repetitive behavior disorders (BFRDB, BFRB)

Body-focused repetitive behavior disorders (BFRDB) are related to impulse control disorder. Some of them are sometimes considered impulse control disorders, but the distinction is difficult to make.
BFRBDs show an irresistible urge, often associated with tension, that is relieved by the act, which has similarities to ICDs. While ICDs are traditionally disorders in their own right, in ICD-11 BFRBDs are now classified within the spectrum of obsessive-compulsive and related disorders, albeit in their own subcategory, emphasizing their complex nature.

BFRDB includes, among other things:

  • Bruxism (teeth grinding)
  • Crepitus (cracking of the finger joints)
  • Dermatophagia (skin biting)
  • Thumb sucking
  • Lip keratosis (lip biting)
  • Morsicatio buccarum (cheek biting)
  • Onychophagia (nail biting)
  • Onychotillomania (nail biting)
  • Rhinotillexomania (nose picking)
  • Trichophagia (hair eating)
  • Trichotillomania (pulling out hair)

4.1. Trichotillomania

Trichotillomania (compulsive hair plucking) showed a 5.34-fold risk of ADHD as well as increased risks of50

  • Obsessive-compulsive disorder: 18.3-fold
  • Borderline personality disorder: 15-fold
  • Anxiety disorders: 10.2-fold
  • Alcohol abuse: 6.13 times
  • Depression: 5.89 times
  • Vitamin D deficiency: 4.2-fold

4.2. Chew nails

A study examined 450 children. 14% of them bit their nails. Among these were found:51

  • ADHD at 74.6 %
  • Oppositional defiant behavior at 36
  • Separation anxiety at 20.6 %
  • Enuresis at 15.6 %
  • Tic disorders at 12.7 %
  • Obsessive-compulsive disorder at 11.1
  • mental retardation at 9.5 %
  • major depressive disorders at 6.7 %
  • profound developmental disorders at 3.2 %

5. Affective disorders (depression / dysphoria / dysthymia / mania / bipolar) - 30 to 61 % (vs. 4.7 to 8.9 % = + 550 %)

Dysphoria with inactivity is an original ADHD symptom and not a symptom of depression. Antidepressant treatment of dysphoria with inactivity would be malpractice.
Depression and dysphoria in ADHD
Of 70 adults with ADHD, 60.7% had had an affective disorder in their lifetime, compared to 25.7% of those not affected 52

5.1. Depression

Depression found

  • according to a large Swedish cohort study in 42.28% (men: 35.60%; women: 40.27%) of adult people with ADHD compared to 4.69% (men: 3.55%; women: 5.87%) of those without.53
  • according to another cohort study at 29.9% (across the age range) and 55.7% vs. 24.3% in a small study of adults with ADHD52
    24
  • a Norwegian cohort study found major depression in 24.5 % (men: 20.3 % women: 28.8 %) of adult people with ADHD compared to 5.8 % (men: 4 %; women: 7.6 %) of those not affected.54
  • In children with people with ADHD:
    • 37 %5556
    • 37.34 % (vs. 7.42 % for people not affected by ADHD) = 5-fold risk of depression or anxiety disorder57
  • For children not affected: 8.9 %56 to 14 % 55
    = 4 times the risk
  • Mood swings (15 - 75 %)58
  • Depressive disorders6
  • A simple survey by www.adhs-chaoten.net, in which 73 people with ADHD took part, revealed that a majority suffer from seasonal fall-winter depression.59 This is quite regularly the result of a vitamin D3 deficiency.
    Vitamin D3
  • In adult people with ADHD: 61.8 %37;
    • Depression (40 to 60 %)60; 25 %38
  • Severe depression (MDD
    • 32 %61
    • At least once in the lifetime of 26.4% of adult persons with ADHD compared to 16.2% of people without ADHD62
    • Major depression (6 %)61
      = 4 to 5 times the risk
  • Depression (adults with ADHD overall: 21.4 %; women 32.1 %, men 19.8 %; ADHD-I 22.3 %, ADHD-C 17.6 %, ADHD-HI 32.5 %)63
  • The population prevalence of major depression is 7.8%. People with ADHD have a prevalence of 18.6%, which is 2.4 times higher.64
  • Adults with the highest 10% of ADHD symptom severity according to ADHD-E are 6.68 times more likely to experience depression than non-affected adults.1
  • A meta-analysis found depression in people with ADHD and those without:65

    • in the total population at
      • 8.6 % to 55 % of persons with ADHD vs. 1.2 % to 12.5 % of people without ADHD
    • in clinical cases with
      • 15.4 % to 39.7 % of persons with ADHD vs. 5.8 % to 39.6 % of people without ADHD
  • Predictors of comorbid depressive symptoms in adults with ADHD are

    • female gender
      • Women with ADHD had a 3.69-fold risk of depression. Women with ADHD who used hormonal contraception (“pill”) had a 5.19-fold risk of depression.66
    • Cyclothymic affective temperament and coping strategies with little positive attitude67
    • emotional dysregulation and dysthymic temperament68

5.2. Dysthymia 6.3 % (vs. 3.4 %)

Dysthymia was found in:

  • Adults with ADHD overall: 7.3 %; women 9.4 %, men 5.4 %; ADHD-I 6.3 %, ADHD-C 7.6 %, ADHD-HI 15 %)63
  • In 6.1% of adult persons with ADHD compared to 3.4% of people without ADHD at least once in their lives62
  • The population prevalence of dysthymia is 1.9%. People with ADHD have a prevalence of 12.8%, which is 6.7 times higher.64
  • Dysthymia 5.7 % vs. 1.4 %52

5.3. Bipolar Disorders - 4.7% to 33.5% (vs. 3.1% to 14.3%)

Bipolar Disorders (“manic/depressive”):

  • 33.5% of adults with ADHD compared to 6.2% of people without ADHD at least once in their lives62
  • 19.4 % in persons with ADHD, 3.1 % population prevalence, i.e. 6.3 times higher.64
  • 6.4 % Adults with ADHD overall (women 8.3 %, men 4.7 %; ADHD-I 5.1 %, ADHD-C 8.0 %, ADHD-HI 10.0 %)63
  • 6 %38
  • 4.7 % (over the entire age range)24
  • In adult psychiatric hospital patients with ADHD: 92.2 %69

  • For those not affected: 14.3 %37

  • Mania 0.15 % (for ADHD over the entire age range)2

  • 57 to 86% of children and adolescents with bipolar Disorder also have ADHD70

One (experimentally unvalidated) hypothesis regards bipolar as an extreme form of ADHD-C. The hypothesis sees ADHD and bipolar as a disorder of the self-regulation of extracellular dopamine levels71
ADHD - like bipolar - suffers from a disorder of self-regulation of the extracellular dopamine level, so that the DAT works partially or completely in the mode of an inappropriately high dopamine efflux, whereby either the range between the lower and upper control limit (at which other influences intervene to stabilize the dopamine level) or the DAT homeostasis feedback is different. Bipolar has a much narrower range of functional extracellular dopamine levels than ADHD. Whereas ADHD-HI remains emotionally balanced with an excessive extracellular dopamine level and ADHD-I with a reduced extracellular dopamine level, so that regulation can be achieved by D2 autoreceptor regulation alone.
without, however, utilizing the appropriate autoregulation of extracellular dopamine levels, is in ADHD-C
A high extracellular dopamine level results from a certain number of DAT working in efflux mode. The D2 autoreceptor can regulate this level to varying degrees, resulting in a state with a high extracellular dopamine level (ADHD-HI) or a low extracellular dopamine level (ADHD-I). In ADHD-C, on the other hand, extracellular dopamine levels fluctuate between too high and too low. Bipolar differs from ADHD-C in that extracellular dopamine levels are even higher than in ADHD-HI and the upper limit of ADHD-C and even lower than in ADHD-I and the lower limit of ADHD-C. An extremely high extracellular dopamine level in bipolarity correlates with a manic phase, an extremely low one with a depressive phase.
In our view, this model is subject to criticism:

  • In ADHD-C, inattentive and hyperactive-impulsive symptoms occur simultaneously, while bipolar clearly alternates between manic and depressive phases.
  • The model of the hypothesis does not differentiate between different brain regions.
  • In our view, it is more conceivable that the extracellular dopamine levels in ADHD-C in different regions of the brain are in different states at the same time.
  • Not all people with ADHD also have bipolar, but this would have to be the case if bipolar were merely a more intense variant of ADHD-C
  • Amfetamine medication works better than methylphenidate in adults with ADHD. Amfetamine causes a DAT efflux - certainly in higher (drug) doses, but it is unclear whether this is also the case in medication doses. If amfetamine also causes DAT efflux in drug doses, amfetamine would have to increase ADHD symptoms according to the hypothesis.

Cyclothymia is another form of affective disorder in which the bipolar mood swings occur at shorter intervals and to a lesser extent than in bipolar.
In our view, cyclothymia would therefore be a more obvious candidate for “attenuated” bipolar than ADHD.

6. Motor clumsiness up to 60

Source6

6.1. Developmental motor coordination disorder, dyspraxia, DCD - 29 % to 47 %

  • 47 % Developmental coordination disorder (DCD, dyspraxia) in persons with ADHD7273
  • over 50 %. An online survey of German parents (n = 149) found a significantly higher prevalence of DCD (over 50%), even if the parents had never heard of DCD74
  • 34% of boys and 29% of girls with ADHD (n = 755)75

Children with DCD were more likely to show ADHD symptoms.76
In an online survey of university students (up to the age of 29) in Japan, 7.4% of participants were found to have dyspraxia (≥ 32 points in the AAC-Q, average 36.2). 17.6% achieved a score ≥ 27. Participants without DCD achieved an average of 19.5 points. ADHD was found in 3.2%. The AAC-Q scores correlated strongly with the results of the ADHD Developmental Disorder Difficulty Scales short (r = 0.65), moderately to strongly with the ASD Developmental Disorder Difficulty Scales short (r = 0.55) and moderately with mental health problems according to the UPI (r = 0.41). The result is in line with other studies that found DCD in 7 to 9% of all young adults77

A combination of ADHD and DCD usually represents a more severe phenotype. Despite some shared neuronal features, ADHD and DCD appear to have a separate etiology.73

Diagnostic criteria according to DSM 5:

  1. The learning and execution of coordinated motor skills (if the opportunity to learn the skills is given) is below the level expected for the age.
  2. The motor difficulties significantly impair the activities of daily life and have an impact on school performance, pre-professional and professional activities as well as leisure and play.
  3. The beginning is in the early development phase.
  4. A doctor cannot better explain motor difficulties by intellectual delay, visual impairment or other neurological conditions that affect movement.

The delay is usually in the acquisition of motor skills. Motor milestones are often not delayed.

6.2. Gross motorist

Frequent accidents, bumping into things, bruises. See also under Symptoms of ADHD.

6.3. Impaired fine motor skills, poor handwriting - 60 %

Up to 60% of people with ADHD suffer from impaired fine motor skills, such as poor handwriting.78

7. Behavioral disorders / social disorders (aggression, antisocial behavior, oppositional defiant behavior) - up to 55 %

  • 30 to 50% of people with ADHD have comorbid ODD or CD.79
  • 30% of adults with ADHD showed some form of social behavior disorder80

7.1 Severe behavioral disorder (disruptive behavior disorders) - 30 to 50 %

Frequency of DBD in children with ADHD:

  • 50 %81
  • 30 to 50% of people with ADHD have comorbid ODD or CD.79
  • 31% in Iran for children between 6 and 18 years of age.82

Newer definition models of externalizing aggressive disorders are

  • Disruptive Mood Dysregulation Disorder (DMDD)83 and
  • Intermittent Explosive Disorder (IED)79

7.2. Deficient Emotional Self Regulation (DESR) - 44 to 55 %

DESR is described as

  1. Self-regulation deficits of physiological arousal caused by strong emotions
  2. Difficulty inhibiting inappropriate behavior in response to positive or negative emotions
  3. Problems with refocusing attention when emotions are strong
  4. Disorganization of behavioral coordination in response to emotional activation
  • DESR is distinct from the persistent and severe aggressive irritability that is common in (rarely occurring) pediatric bipolar Disorder84
  • The abnormal moods of bipolar Disorder are not due to poor self-control and include other DSM-IV mood criteria. DESR is not associated with an increased risk of bipolar Disorder.85

Among people with ADHD, DESR was found in

  • 55 %86

  • 44 %85

  • In 2 % of the non-ADHD people with ADHD.85

DESR is diagnosed if the person with ADHD scores between 180 and 210 points on the 3 scales of anxiety/depression (intense emotions), aggression and attention (impulsivity) of the Child Behavioral Check List (CBCL) (on average between 60 and 70 per scale). Scores above 210 points are no longer referred to as DESR, but as more severe forms of affective disorders (mood and behavioral dysregulation disorders). Due to the defined diagnostic criteria of DESR, which cannot be achieved without a high score on the aggression scale, the diagnosis of DESR is likely to be limited to the ADHD-HI subtype, which is phenotypically more likely to react to perceived stress with aggression
The CBCL scale for aggressive behavior:87
1. Argues or disagrees a lot
2. Specifies, cuts to
3. Is crude or mean to others, intimidates them
4. Requires a lot of attention
5. Breaks his own things
6. Breaks things that belong to parents, siblings or others
7. Does not obey at home
8. Does not obey at school
9. Is easily jealous
10. Easily gets into fights, arguments
11. Physically attacks others
12. Screams a lot
13. Likes to produce or clown around
14. Is stubborn, grumpy or irritable, is easily annoyed by others
15. Shows sudden changes in mood and emotion
16. Talks too much
17. Likes to tease others
18. Has outbursts of anger or a hot temper
19. Threatens, bullies or intimidates others
20. Is unusually loud

According to our assessment, all question topics are primarily aimed at the ADHD-HI subtype (with hyperactivity), while only question topics 7, 8, 9, 14 and 15 also fit the ADHD-I subtype, but do not specifically ask about possible symptoms of inwardly directed emotional intensity. In the predominantly inattentive subtype (ADHD-I), barely any externalizing symptoms such as aggression or oppositional defiant behaviour occur.88 According to our understanding, the ADHD-I subtype internalizes perceived stress and does not primarily react aggressively.

DESR can therefore only occur with this symptom selection in people with ADHD-HI and ADHD-C, not in ADHD-I.
We assume that people with ADHD-I also suffer from emotional dysregulation, which just does not or rarely manifests itself as aggression. This perception was confirmed by an ADHD therapist in a personal interview.

Consequently, significantly more than 44 to 55% of all people with ADHD are likely to suffer from emotional dysregulation, although the forms of expression can vary greatly
Here, too, studies would be desirable that take into account the subtypes and the phenotypic expression of intense emotions (ADHD-HI: externalization / ADHD-I: internalization).

7.3. Oppositional Defiant Disorder (ODD) - 26 to 53 % (vs. 3.9 % = + 560 % to + 1,260 %)

  • 60% ODD prevalence in children with ADHD80 We consider this to be a translation. In our opinion, this could be true at best when considering only boys with severe ADHD-HI. In addition, * the prevalence figures by gender do not match the overall prevalence stated:
    • 55 % for boys
    • 30 % for girls
    • 30% in adults for the entirety of social behavior disorders in ADHD80
  • 53 % in children and adolescents with ADHD-C89
    • 63 % with ADHD-C and ASD89, with 80 % of people with ADHD-C also showing ASD
    • 28 % for ADHD-I and ASD89
    • 24 % for ASA89
    • 14 % for ADHD-I89
  • 39.3 % in children with ADHD90
  • 35 % ODD in children with ADHD91
  • 26.1 % in Iranian children with ADHD between 6 and 18 years of age82
  • 0.7 % ODD in adults with ADHD (women 0.0 %, men 1.7 %; ADHD-I 0.0 %, ADHD-C 1.5 %, ADHD-HI 5.0 %)63

ODD in non-affected people: 3.9%37
= 8 to 15 times the risk

  • ODD refers primarily to people with ADHD-HI (with hyperactivity) and less to people with ADHD-I (without hyperactivity), as hyperactivity is an outgrowth of an externalizing stress response pattern, while ADHD-I is an outgrowth of an inwardly directed stress (playing dead, fleeing). The subtypes of ADHD: ADHD-HI, ADHD-I, SCT and others
  • We understand ODD (Oppositonal Defiant Disorder) as a pure comorbidity to ADHD, i.e. not as ADHD symptoms.
    • Steinhausen describes disorders of social behavior on the one hand as the most common comorbidity of ADHD,92 describes the comorbidity on the other hand on page 174 as a subtype of ADHD.
    • Apart from the fact that sleep disorders are likely to be significantly more common, we do not consider ODD to be a subtype due to the delimitability of the genetic basis.
      • A specific polymorphism of the MAO-A gene is cited as a genetic contributory cause of both social behavior disorders and ADHD (in each case as one of several interacting specific genes). However, this gene polymorphism seems to play a much greater role with regard to social behavior disorders, as it is mentioned much more frequently there and ADHD can also manifest itself without the involvement of this gene (through the interaction of other genes). In the case of ADHD, the MAO-A gene is always mentioned in a subset of people with ADHD who also suffer from behavioral disorders.
      • A further argument in favor of pure comorbidity is that non-specific ADHD medications such as risperidone only reduce aggressiveness but not ADHD symptoms, while MPH (methylphenidate) can alleviate the symptoms of ADHD and ODD equally.93
  • ODD does not correlate with any of the symptom circuits of the dual / triple pathway model, so at least in this respect it has a different neurological basis.94

Symptoms of Oppositional Defiant Disorder (ODD):

  • Frequent and persistent defiance or disobedience towards authority figures
  • Quarrelsome and easily irritated or annoyed
  • Deliberate attempts to annoy others or behave vindictively
  • Difficulty following rules and displaying a pattern of negative, hostile and defiant behavior

7.4. Disorders of social behavior / Conduct Disorder (CD) - up to 20.2 % (vs. 4.3 %)

Conduct Disorder (CD) is more common in ADHD.6

  • 20.2% of adult persons with ADHD compared to 4.3% of people without ADHD at least once in their lives62
  • 16 % in children with ADHD (boys 18 %, girls 8 %)80
  • 1.2 % in adults with ADHD overall: 1.2 %; women 0.7 %, men 1.7 %; ADHD-I 0.3 %, ADHD-C 1.0 %, ADHD-HI 10.0 %63

Persons with Disorder of Social Behavior have 21 times the risk (compared to people with ADHD) of also suffering from ADHD.95
Disorders of social behavior and aggression disorders have their own genetic disposition in a specific polymorphism of the MAO-A gene. How ADHD develops: genes or genes + environment

The population prevalence of conduct disorder in children and adolescents was determined by an Iranian study:96

  • 0.58 % for children aged 6 to 9 years
  • 0.57 % for adolescents aged 10 to 14 years
  • 1.22 % for young people aged 15 to 18

32% also met the criteria for ADHD, 55% the criteria for ODD.

Symptoms of conduct disorder (CD):

  • Aggressive or violent behavior
    • Frequent physical altercations
    • Harm to humans or animals
    • Bullying or cruelty
  • Antisocial behavior
    • Frequent disregard for the rights of others
  • Recurring and persistent patterns of difficulties in accepting norms
    • Destruction of property
    • Participation in thefts
    • Fraudulent behavior
    • Lies
  • Lack of remorse or feelings of guilt for one’s own actions
    • Lack of empathy

7.5. Aggressive behavior - over 50

Slightly more than 50 %97

Aggressive behavior is not an original symptom of ADHD-HI. Aggressiveness can be an expression of stress, but not everyone reacts to stress with aggression, nor does everyone externalize stress.
One of the arguments in favor of pure comorbidity is that non-ADHD-specific drugs such as risperidone only reduce aggressiveness but not ADHD symptoms, while MPH (methylphenidate) can alleviate the symptoms of ADHD and ODD in equal measure.93

Reduced cortisol levels have been reported in ADHD in conjunction with aggression disorders.98
Externalizing stress reactions are associated with lower basal cortisol levels and a reduced cortisol response to acute stress.
Disorders of stress hormone levels, especially cortisol, are extremely common in ADHD.
Cortisol in ADHD

See also Neurophysiological correlates of aggression

8. Anxiety disorders - up to 47 % (vs. 19.5 %)

47.1 % among people with ADHD, i.e. around 2.4 times higher64

The population prevalence of anxiety disorders is 19.5%.99
Generalized anxiety disorder (a form of anxiety disorder) affects up to 5% of children and adolescents and between 3 and 6% of adults.100

There was no genetic overlap between ADHD and anxiety disorders. Genes that correlated with high intelligence showed a protective factor against ADHD, but not against anxiety disorders.101

8.1. Anxiety disorders in children - 25 to 38 % (vs. 7 to 10 % = up to + 400 %)

The prevalence of anxiety disorders in children with ADHD was:

  • 37.9% in Iranian children with ADHD between the ages of 6 and 18.82
  • 37.34 % (vs. 7.42 % for people not affected by ADHD) = 5-fold risk of depression or anxiety disorder57
  • 37 % over the entire age range24
  • 34 %102,
  • 25 %103
  • 25 % 91,
  • Increased (without % indication)104

The population prevalence of anxiety disorders is

  • Around 10 %105
  • 7,42 %57
    = 3 to 5 times the risk
  • Anxiety disorders and ADHD seem to reinforce each other. Treating anxiety or AD(HS also reduces the symptoms of the other Disorder.106
  • Generalized anxiety disorder tripled and a half the risk of ADHD, while ADHD quadrupled the risk of generalized anxiety disorder.107
  • 40 to 85% of children with an anxiety disorder also had ADHD108

8.2. Anxiety disorders in adults - 44 % (vs. 4.9 %)

According to a large Swedish cohort study, an anxiety disorder was found in

  • 4.3 % to 47.1 % of persons with ADHD vs. 0.5 % to 9.5 % of people without ADHD (meta-analysis)65
  • 44.65% (men: 37.02%; women: 55.74%) of adult people with ADHD compared to 4.89% (men: 3.64%; women: 6.19%) of people without ADHD53
  • 42 % or 20 to 60 % in adults with ADHD60
  • 34.3% of adults with ADHD at least once in their lives, compared to 25.7% of those not affected52
  • 34.5 % (19 % anxiety disorders and 15.5 % phobic disorders)38
  • 22.2 % (men: 18.2 % women: 26.3 %) among adult persons with ADHD compared to 5 % (men: 3.3 %; women: 6.7 %) of people without ADHD (Norwegian register study)109

Among adult psychiatric inpatients with ADHD

  • 3.9 % to 84 % for inpatients with ADHD vs. 5.4 % to 40 % for psychiatric inpatients without ADHD (meta-analysis)65
  • 28,6 %69
  • 25 %103

Anxiety disorders and ADHD seem to reinforce each other. Treating anxiety or AD(HS also reduces the symptoms of the other Disorder.106

8.2.1. Generalized anxiety disorder - 5.9 to 25 % (vs. 2 %)

  • 8 % among people with ADHD, vs. 2.6 % population prevalence, i.e. around 3 times higher.64
  • In adult people with ADHD:
    • 25 %61
    • 5.9 % among adults with ADHD (women 7.6 %, men 4.4 %; ADHD-I 7.1 %, ADHD-C 3.5 %, ADHD-HI 7.5 %)63
    • 2.9% of adults with ADHD at least once in their lives compared to 1.4% of those not affected52

Population prevalence: 2 %61

8.2.2. Social phobia - 5 to 29.3 % (vs. 3.5 to 10 %)

  • 29.3 % among people with ADHD, vs. 7.8 % population prevalence, i.e. almost 3.8 times higher.64
  • 22.8% social anxiety disorder among adult persons with ADHD compared to 6.6% among non-affected people at least once in their lifetime.62
  • 18.6% of adults with ADHD at least once in their lives, compared to 10% among those not affected52
  • 3.5 % among adults with ADHD (women 2.5 %, men 4.4 %; ADHD-I 3.3 %, ADHD-C 3.0 %, ADHD-HI 7.5 %)63

8.2.3. Panic disorder - 1.9 to 4.3 % (vs. 2.9 %)

  • 22% of adults with ADHD compared to 7% of people without ADHD at least once in their lives62
  • 8.9 % among people with ADHD, population prevalence 3.1 %, i.e. almost 3 times higher.64
  • 4.3% of adults with ADHD at least once in their lives, compared to 2.9% of those not affected52
  • 1.9 % among adults with ADHD (women 2.9 %, men 2.4 %; ADHD-I 2.1 %, ADHD-C 2.5 %, ADHD-HI 7.5 %)63

8.2.4. Specific phobias

  • 35.8% of adult persons with ADHD at least once in their lives compared to 14.6% of non-affected people 62

  • 22.7 % among people with ADHD, population prevalence 9.5 %, i.e. almost 2.4 times higher.64

  • Agoraphobia:

    • 4.0 % among people with ADHD, population prevalence 0.7 %, i.e. around 5.7 times higher.64

9. Substance abuse and addiction - up to 45

A meta-analysis found addictive disorders:110

  • in the total population at
    • 2.3 % to 41.2 % of persons with ADHD vs. 0 % to 16.6 % of people without ADHD
  • in clinical cases with
    • 10 % to 82.9 % of persons with ADHD vs. 2 % to 72.2 % of people without ADHD

Among patients of addiction centers, ADHD serial studies found 21 to 23% of people with ADHD111, which corresponds to 4.6 to 9.2 times the adult ADHD population prevalence of 2.5 to 5%. One study found 45% of people with ADHD112, which corresponds to 10 to 20 times this figure

9.1. Substance-related addictions / substance abuse

Of n = 873 patients in a psychiatric emergency department in an emerging urban county in North Carolina (USA) with ICD10 diagnoses of anxiety, depression, schizophrenia, ADHD, bipolar disorder, alcohol abuse, or schizoaffective disorder showed:113

  • 58% of patients with a psychiatric history have a positive urine drug test
  • ADHD (n = 135)
    • 34.7 % alcohol
    • 20.2 % THC
    • 15.3 % Cocaine
    • 14.9 % Paracetamol
    • 12.9 % Benzodiazepines
    • 12.1 % Opiates
    • 8.1 % Amfetamine drugs
    • 1.6 % barbiturates
  • Depression (n = 225)
    • 40.8 % Paracetamol
    • 25.6 % THC
    • 20.9 % alcohol
    • 15.0 % Opiates
    • 13.7 % Benzodiazepines
    • 12.6 % Cocaine
    • 7.4 % Amfetamine drugs
    • 2.1 % barbiturates
  • States of anxiety
    • 30.8 % THC
    • 10.3 % alcohol
    • 5.1 % Opiates
    • 5.1 % Cocaine
    • 4.7 % paracetamol
  • bipolar disorders
    • 29.4 % THC
    • 27.3 % alcohol
    • 16.9 % Opiates
    • 13.0 % Cocaine
    • 10.4 % Benzodiazepines
    • 9.2 % Paracetamol
    • 8.2 % Amfetamine drugs
  • Schizoaffective Disorder (n = 245)
    • 26.1 % THC
    • 25.6 % alcohol
    • 24.4 % Paracetamol
    • 20.8 % Cocaine
    • 12.1 % Benzodiazepines
    • 8.7 % Opiates
    • 5.1 % Amfetamine drugs
    • 2.5 % barbiturates
  • Schizophrenia (n = 45)
    • 32.6 % THC
    • 14.4 % alcohol
    • 10.9 % Cocaine
    • 5.5 % paracetamol
    • 8.7 % Benzodiazepines
    • 2.2 % opiates

Overall, there was no significant correlation between the psychiatric diagnosis and positive drug screening.113

9.1.1. Substance abuse - 21.9 % to 35 % (vs. 2.9 % to 3.6 %)

  • 35.12% (men: 39.44%; women: 30.88%) of adult persons with ADHD compared to 3.61% (men: 4.40%; women: 2.79%) of people without ADHD (large Swedish cohort study)53
  • 21.9 % (men: 27.5 %; women: 16.2 %) of adult persons with ADHD compared to 2.9 % (men: 3.6 %; women: 2.1 %) of people without ADHD (large Norwegian cohort study)114

Among adult SUD patients in three drug rehabilitation centers in urban Malaysia, ADHD prevalence was 47.2%. SUD affected persons with ADHD were less likely to have medical comorbidities (84.9% vs. 93.3%), more likely to have a history of incarceration (80.8% vs. 65.6%) and more likely to have a first incarceration before the age of 18 years (24.6% vs. 16.8%) compared to SUD affected persons.115

Substance abuse is a common comorbidity of ADHD.6 One possible connection could be that dopamine deficiency leads to an increased expression of CB1 cannabinoid receptors.116117118 THC binds to CB1 receptors.

Of 70 adults with ADHD, 17.1% had experienced substance misuse in their lifetime, compared to 2.9% of those without52
People with ADHD showed an ADHD prevalence of 21% (meta-analysis).119
Among 153 addicts (98.7% males) at a clinic in India, 33% were found to have ADHD. The prevalence of ADHD was different for certain addictions:120

  • 47.6 % of people with cannabis addiction
  • 38.8 % of people who use tobacco/smoke
  • 33% of people with cocaine addiction and
  • 21.5 % of people with alcohol dependence.
  • The prevalence of ADHD among opioid addicts was around 50%. ADHD symptoms, especially impulsivity, increase the risk of opioid addiction. 121
  • For people with ADHD, substance abuse begins on average 3 years earlier122
  • Appropriate medication (especially methylphenidate) reduces the likelihood of addiction or substance abuse in ADHD.
  • People with ADHD with comorbid cocaine addiction showed a significant reduction in addictive behavior when treated with stimulants, corresponding to a decrease in ADHD symptoms.123

A small Norwegian cohort study found no association between ADHD and alcohol or drug abuse,124 as well as an earlier study,125 which found increased alcohol and drug abuse in people with ADHD only in the presence of additional externalizing disorders.
However, these studies clearly contradict the vast majority of specialist literature, which reports a significant risk increase in ADHD.

9.1.2. Smoking - 40 to 45 % (vs. 22 to 25 %)

Among adult people with ADHD who smoked

  • 44,8 %62

  • 42 %126127

  • 40 % 128

  • 51% of adult psychiatric inpatients with ADHD are addicted to nicotine69

Among people with ADHD who did not smoke

  • 27% of women and 32% of men in the total population aged 18 and over129
  • 26 % (2005)130
  • 22.6 %62

The risk of smoking is therefore almost doubled with ADHD (regardless of medication).
Among adult people with ADHD-HI/ADHD-C, the risk of smoking is doubled.131

ADHD medication, nicotine (smoking) and zinc block the dopamine transporters (DAT) (which are elevated in ADHD) and thus reduce their overactivity132

9.1.3. Alcohol dependence (30 to 39 % vs. 5 to 15 %) / alcohol abuse

The German guidelines now stipulate an ADHD examination as a standard procedure for alcohol addiction.

Alcohol dependence is drastically increased with ADHD133

  • In adult people with ADHD
    • 38,9 %62
    • 30 %61, 25 to 44 %131
    • 8.6% of adults with ADHD at least once in their lives, compared to 2.9% of those not affected52
    • 4.1 % in adult psychiatric inpatients with ADHD69
  • For non-affected persons
    • 5 %61 up to 14.662

= 6 to 8 times the risk

Conversely, among n = 153 alcoholics, 43% were found to have childhood ADHD and 22% were found to have persistent ADHD.134 Another study found an ADHD diagnosis in 19% of 100 adult alcoholics in India.135

Alcohol / substance abuse:

  • 1.6% of adults with ADHD showed alcohol or substance misuse (women 1.1%, men 2.0%; ADHD-I 0.9%, ADHD-C 2.5%, ADHD-HI 2.5%)63

  • 18.1 % to 22.6 %62 compared to 19.3 % for those not affected62

  • A small Norwegian cohort study found no association between ADHD and alcohol or drug abuse,124 as well as an earlier study,136 which found increased alcohol and drug abuse in people with ADHD only in the presence of additional externalizing disorders.

For alcohol dependence, 6 parameters predicted the presence of comorbid ADHD with an AUC of 0.926:.133

  • reduced self-control
  • increased novelty seeking
  • Self-transcendence
  • Damage prevention
  • Craving
  • early first consumption of alcohol

Self-steering and novelty seeking together achieved an accuracy of 85%.133

9.1.4. Substance-related addictions in general - 7.8 %

  • In adult persons with ADHD: 7.8 %37, 20 %61 to 50 to 60 %137138
  • For those not affected: 1.9 %37 to 5 %61138
    = 4 to 12 times the risk
  • According to another source, the lifetime prevalence of psychoactive substance use in people with ADHD is 52%, compared with 24% in people without the disorder.139
  • Of 70 adults with ADHD, 11.4% had a substance dependence in their lifetime, compared to 0% of the 70 unaffected52

9.1.5. Drug addiction

  • The population prevalence of drug addiction is 0.6%. People with ADHD have a prevalence of 4.4%, which is around 7.3 times higher.64
  • Among adult psychiatric clinical patients with ADHD, 7.1% have comorbid drug dependence.69
  • Drug addicts are 4 to 5 times more likely to have ADHD140
  • 15.5%141 to 25% of all addicts have ADHD142
  • ADHD was found in 11.2% of all adult addiction patients who used intravenous opiods or intravenous/intranasal benzodiazepines. The ADHD rate was higher among women (15.3 %) than among men (10.3 %).143
  • With ADHD, the risk of substance dependence (addiction) is 2 to 3 times higher than for those not affected.144
  • The risk of nicotine dependence is up to 9 times higher in those with ADHD than in those without.144
  • Persons with ADHD are about as likely to be addicted as relatives who are not affected by ADHD.
    • Cannabis: 67 vs. 72 %138
    • Cocaine: 23 vs. 21 %138
    • Stimulants: 18 vs. 10 %138
    • Hallucinogens: 18 vs. 7 %138
    • Opioids: 16 vs. 3 %138
    • Sedatives: 14 vs. 10 %138
  • According to one study, 12% of cocaine users had ADHD in childhood and 10% still had it as adults.145

9.2. Behavioral addiction / gambling 5.3 % (vs. 2.4 %)

People with ADHD have more than double the risk of developing a gambling addiction (5.3% compared to 2.4%). Problem gambling behavior is 4 times more common among persons with ADHD (2.4%) than among people without ADHD (0.6%).146
Another study found gambling addiction in 1.54% of adult persons with ADHD compared to 0.39% of non-affected people at least once in their lifetime.62

A study of n = 97 gambling addicts found an ADHD rate of 26.0 % and an ASD rate of 29.8 %.147
One study found that gene variants that correlate with substance use can causally increase the risk of ADHD.148

9.3. Substance abuse (illegal drugs: 10 %, nicotine: 16.6 to 25.5 %)

Among adults with ADHD, the prevalence of substance abuse is 33.5%.149 The risk of substance abuse among adults with ADHD in the USA is 1.7 to 7.9 times higher.150

The prevalence of substance abuse among German adults in 2019 was (12-month prevalence and lifetime prevalence)151
Cannabis: 7.1 % / 28.3 %
Cocaine / crack: 1.1 % / 4.1 %
Ecstasy: 1.1 % / 3.9 %
Amphetamines: 1,2 % / 3,8 %
Methamphetamine / crystal meth: 0.2 % / 0.8 %
Smoking (at least 20 cigarettes/day), adults:152

  • Men: 25.5 %
  • Women 16.6 %

Alcohol:153

  • Risky consumption within 12 months
    • Men 15.6 %
    • Women 12.8 %

One study found an ADHD prevalence of 20.5% among patients hospitalized for alcohol dependence.154

If aggressive and oppositional defiant behavior and low self-esteem are present in addition to ADHD, the probability of substance abuse is significantly increased, while no more frequent substance abuse was found in adolescent people with ADHD without these additional symptoms.155156

In our opinion, substance abuse is much more likely to be a consequence of ADHD than the cause of a full ADHD symptom picture. In rarer cases, it is comorbid. Treatment with stimulants very often eliminates the addictive tendency in ADHD. Modern dosage forms of stimulant medications are barely suitable for abuse as a drug (e.g. Vyvanse: prodrug of amphetamine bound to lysine, which is only very slowly converted to the active ingredient in the intestine).

In the Continuous Performance Test, people with ADHD showed more responses to correct timing compared to those with substance abuse.157

9.4. Addiction / dependency (alcohol: 5%, gambling: 0.31%)

Prevalence: Present in 24.9% of adults with people with ADHD.158

Alcohol:153

  • Dependence
    • Men 4.8 %
    • Women 2 %
  • Abuse
    • Men 4.6 %
    • Women 1.5 %

In Berlin, 5.0% of 15- to 64-year-old respondents met the criteria for alcohol dependence according to DSM-IV (men: 6.4%, women: 3.5%).159

In Germany, the prevalence of gambling addiction is 0.31% and the prevalence of problematic gambling behavior is 0.56%.160
A study of n = 97 gambling addicts found an ADHD rate of 26.0 % and an ASD rate of 29.8 %.147

In the case of comorbidity of ADHD and addiction, there is an increased probability that ADHD is the causal cause of the addiction and not addiction the cause of ADHD. This was shown at least for smoking, cannabis and probably also alcohol.161

One study found that increased polygenic risk scores (PRS) for ADHD also increased the likelihood of addiction by 20%. There were no differences with regard to the intensity of the addiction (use, abuse, dependence) or the type of addictive substance (alcohol, cannabis, other illegal drugs). Conversely, the ADHD-PRS explained only 0.2% of the probability of addiction compared to other risk factors.162

One study showed an ADHD prevalence of 16.7% in severe addicts compared to 2.5% in the control group.163
Even more significant was the fact that 53% of severe addicts had socially disturbed behavior in childhood or adolescence (up to 15 years), as measured by the SKID-II (control subjects with 2.5%).164 An earlier Disorder of Social Behavior (OR = 35.1) compared to childhood hyperkinetic behavior (OR = 5.7) is by far the greater risk factor for severe addiction.165
This indicates to us that addiction plays a role predominantly in ADHD-HI and less in ADHD-I.
The preference for addictive substances indicates a more frequent use of cannabis products among people with (former) hyperkinetic behavior. There appears to be no significant difference for opiates, cocaine, amphetamines, sedatives and hallucinogens.166
Although a joint occurrence of hyperkinetic and socially disturbed behavior is associated with an early first use of illegal drugs, statistically only an earlier and increased use of nicotine could be proven.166
Adults with ADHD and addiction had a lower age of onset of substance use and used as an addictive substance:167

  • more frequently: alcohol, cannabis, methamphetamine, tramadol
  • less frequently: methylphenidate, methadone, ecstasy, morphine, hypnotics

Long-term abuse of dopaminergic drugs (cocaine, amphetamines) leads to prolonged downregulation of dopamine levels. Withdrawal symptoms then correspond to ADHD symptoms. 168 Against this background, the question arises as to whether ADHD medications (stimulants), which are known to have no intoxicating effect, could be helpful in the withdrawal of dopaminergic drugs.
People with ADHD with comorbid cocaine addiction showed a significant reduction in addictive behavior when treated with stimulants.123

Common symptoms of addiction / substance abuse and ADHD:49

  • Impulsiveness
  • (Inner) restlessness, motor hyperactivity
  • Concentration problems
  • High flow of speech (logorrhea, polyphrasia)

ADHD symptoms that are atypical for addiction / substance abuse:

  • Chasing thoughts, circling thoughts
  • Attention problems
  • Dysphoria with inactivity
  • Mood swings

Symptoms of addiction / substance abuse that are atypical for ADHD:

  • Substance abuse:
    • Excessive consumption of a substance, even if there are serious Consequences
  • Addiction / dependence:
    • Excessive consumption to the point of dependence on the drug
    • Very difficult to stop

10. Restless legs (RLS, akathisia) - 11 to 44 % (vs. 2.6 to 15.3 %)

A meta-analysis found RLS in 11 to 42.9 % of children with ADHD and in 20 - 33.0 % of adults with ADHD. In the general population, RLS was found in 2.6 to 15.3%.169
A study of children with ADHD (aged 6 to 16) found RLS in 33.3%.170 Other sources speak of 44%.171 A smaller study of adults with ADHD found RLS in 20%, with comorbid RLS aggravating ADHD symptoms.172
Kooij sees RLS in 30 % to 40 % of people with ADHD.36
One study found 10% of people with ADHD had a disorder of periodic limb movements (PLMS) (more than 5/h).173 Another study found 66% of children with ADHD had a PLM index greater than 5/h, which is a marker for RLS, while no ADHD non-affected individuals had an elevated PLM index.174 A meta-analysis found no evidence of more frequent PLMS in ADHD.175
In adult psychiatric clinical patients with ADHD, 25.5% showed RLS69
A large cohort study found a strong correlation between restless legs and ADHD.176

ADHD is found in up to 26% of people with ADHD.171

Irrespective of ADHD, RLS occurs in around 2% of all children and adolescents, and in 0.5 to 1% in moderate to severe form. In adults, it affects 5 to 10 %. In 25% of people with ADHD, the disorder begins between the ages of 10 and 20.177 Other sources cite a prevalence of RLS of up to 8%.178
In 70% of people with ADHD, one parent is also affected.

A genetic link between RLS and ADHD has not yet been established. It is conceivable that the BTBD9 gene, which is associated with iron stores, could be involved.
69.4% of children and adolescents with RLS have sleep disorders (vs. 39.6% of those not affected), 80.6% have a history of “growing pains” (vs. vs. 63.2% of those not affected).178

Common causes of RLS and ADHD

10.1. iron deficiency in RLS and ADHD

There is increasing evidence that iron deficiency (S-ferritin level < 12 ng/ml) underlies common pathophysiological mechanisms in patients with RLS and patients with ADHD-HI178
Iron is a cofactor for tyrosine hydroxylase, an enzyme that is essential for dopamine synthesis. ADHD and RLS both often show decreased iron levels. Lower S-ferritin levels in people with ADHD correlate with more severe ADHD-HI symptoms. Children with ADHD and RLS showed lower ferritin levels than children with ADHD without RLS.179180181 However, other studies did not find decreased S-ferritin levels in ADHD 182183
In RLS, the severity correlates more clearly with a reduced S-ferritin level.184185 particularly in children.186 It is possible that impaired transport of iron from the serum into the cerebrospinal fluid and of iron into the dopaminergic cells leads to a reduced iron concentration in the cerebrum.187 Adults with RLS show a low iron status in the cerebrum.188
Children with ADHD and a predisposition to RLS appear to represent a subgroup at particular risk for severe ADHD-HI symptoms, and iron deficiency may contribute to the severity of ADHD symptoms.179
An RC study found improved ADHD symptoms in children with ADHD and low ferritin levels when given iron (80 mg/day).189

10.2. adenosine for RLS and ADHD

Restless legs could be caused by downregulation of adenosine A1 receptors as a result of iron deficiency.190
Adenosine is closely linked to dopamine. Adenosine receptors are found throughout the brain in the vicinity of dopamine receptors and sometimes form receptor heteromers with them. Adenosine could also be involved in ADHD, although more likely via an excessive adenosine effect on adenosine A2A receptors. Adenosine inhibits dopamine, adenosine antagonists such as caffeine (coffee, cola, black tea) and theobromine (cocoa) therefore increase dopamine.
More on this in the article =&gt Adenosine

10.3. treatment of RLS in ADHD

The problem with the comorbidity of restless legs and ADHD is that ADHD medications (although also dopaminergic) do not work against RLS and RLS medications such as L-dopa (although also dopaminergic) do not work against ADHD.191178192
Prolonged treatment with L-dopa often leads to a worsening of RLS symptoms.
Simultaneous administration of L-dopa and stimulants may cause increased side effects.

A single case report documented a good response of a 6-year-old boy with ADHD and RLS, who was also an MPH nonresponder, to the dopamine agonist ropinirole, in terms of ADHD as well as RLS.193

11. Partial performance disorders - up to 40

Source6

One study found that 6.6% of children between the ages of 7 and 11 had learning-specific partial performance disorders. Reading difficulties were found in 4%, dyscalculia in 3.6% and a weakness in written expression in 1.8%. Approximately 63% of children with learning-specific partial performance disorders had one or more comorbid diagnoses, with ADHD being the most common comorbidity at 54.9%. Boys were more frequently affected.194

11.1. Reading difficulties, dyslexia, dyslexia - 8 to 40 % (vs. 5.6 %)

A distinction must be made:

  • Reading and spelling difficulties (LRS): acquired temporary weakness, usually caused by external circumstances
  • Dyslexia: genetically caused disorder in the area of reading and writing that cannot be overcome through normal practice
  • Dyslexia (reading difficulty): Limited ability to read and understand words or texts, despite normal vision and hearing. Tool disorder.
  • Alexia: complete loss of reading ability

8 - 39 %195196 , 25 - 40 %84, 40 %102

Dyslexia and ADHD have a relevant genetic correspondence.197198 There is no evidence of mutual causality.198
One study found only weak evidence of concordant neurophysiological changes in ADHD and dyslexia.199

6-year-old children with reading difficulties are around 4 times more likely to have ADHD in the teacher assessment (21.0% instead of 5.6%) and around twice as likely to have ADHD in the parent assessment (30.5% instead of 17.8%) than children without reading difficulties.200
There is evidence that reading impairment with ADHD shows different connectivity in the brain than reading impairment without ADHD.201

65 to 70 % of all children with dyslexia are said to have functional binocular disorders:202

  • Oculomotor dysfunctions (OMD) (9 %)
    • Fixation impaired
    • Subsequent movements impaired
    • Horizontal eye saccades impaired
  • Dysfunctional binocular vision (DBS) (16%)
    • Heterophoria
    • Suppression
    • Convergence insufficiency
    • Accommodative dysfunction
    • Fusion insufficiency
    • Stereopsis insufficient
  • DBS and OMD (51 %)
  • Neither DMS nor OMD (24 %)

A study of 1260 children in Pakistan found dyslexia in 21.2% and ADHD in 7.6%:203

  • for 192 dyslexia (15.2 %)
  • for 76 Dyslexia and ADHD (6.0 %)
  • with 20 ADHD (1.6 %)

11.2. Spelling difficulties (agraphia, dysgraphia) - 12 to 40 %

12 - 27 %5, 25 - 40 %84, 40 %102
Also for adults with ADHD.204

11.3. Dyscalculia 12 - 27 %

12 - 27 %5
A meta-analysis found that reading problems correlate more strongly with math problems than with ADHD.205
Also for adults with ADHD.204
ADHD and dyscalculia appear to have common genetic causes. No evidence of mutual causality was found198

Math performance is said to correlate less with ADHD than with executive function problems in ADHD.206 Math problems correlated with working memory problems in ADHD, but not with anxiety.207

11.4. Weakness in facial recognition (prosopagnosia)

It is unclear whether facial recognition deficits are more common in ADHD. There are sources for this208 and against it209.

11.5. Name recall weakness

A weakness in remembering names is said to occur more frequently with ADHD.208

11.6. Speech disorders

Speech disorders are said to occur more frequently with ADHD.6

11.7. Right-left weakness

Right-left weakness correlates with ADHD.210
The overall prevalence of right-left weakness among medical students was 14.7%.

12. Developmental disorder - up to 37.4

Developmental disability (adults with ADHD overall: 24.7 %; women 25.6 %, men 23.8 %; ADHD-I 22.6 %, ADHD-C 25.6 %, ADHD-HI 37.5 %)63

12.1. Specific developmental disorders - 37.4 % (vs. 13.4 %)

  • In children with people with ADHD: 37.4%37
  • For those not affected: 13.4 %37
    = 3 times the risk

12.2. Specific developmental disorders of school skills - 23% (vs. 2.8%)

  • In children with people with ADHD: 23.0%37
  • For those not affected: 2.8%37
    = 8 times the risk

13. Bipolar Disorders - 4.5 to 35.5% (vs. 0.2 to 3.6%)

Bipolar Disorder was found in

  • 14.29% (men: 9.95%; women: 18.95%) of adult persons with ADHD compared to 0.72% (men: 0.53%; women 0.91%) of people without ADHD (large Swedish cohort study)53
  • 10.9 % (men: 8.9 % women: 12.9 %) of adult people with ADHD compared to 1.3 % (men: 1.1 %; women: 1.6 %) of those not affected.54
  • 6 %38; (adults with ADHD overall: 6.4 %; women 8.3 %, men 4.7 %; ADHD-I 5.1 %, ADHD-C 8.0 %, ADHD-HI 10.0 %)63
  • 5.1% of adult psychiatric clinical patients with ADHD69
  • 4.7 % (over the entire age range)24

In 2.4 million people examined, 9250 bipolar disorders were observed. If an ADHD disorder was already present, the risk of bipolar disorder increased 12-fold over a lifetime; if ADHD and an anxiety disorder were previously present, the risk increased 30-fold compared to people without ADHD and without an anxiety disorder.211

People with ADHD have an ADHD prevalence of:

  • 60 % (meta-analysis of twenty studies with n = 2,722 PBD patients (average age = 12.2 years)212
  • 27 % in euthymic people with ADHD213
  • 25% (n = 703 adult people with ADHD), with males and BP type I more likely to have ADHD comorbidity214
  • 3.06-fold increase215

A meta-analysis found Bipolar Disorder in people with ADHD and non-affected people:65

  • in the total population at
    • 4.48 % to 35.5 % of persons with ADHD vs. 0.2 % to 3.6 % of people without ADHD
  • in clinical cases with
    • 7.4 % to 80 % of persons with ADHD vs. 2 % to 19.5 % of people without ADHD

One study found evidence of overlap between the genetic causes of bipolar and ADHD, particularly in early-onset bipolar (under the age of 21),216 another study also found genetic overlap between bipolar and ADHD.217

14. Personality disorders (in adults) - 11.5 % to 33.2 % (vs. 0.9 % to 1.4 %)

Personality disorders are generally not yet diagnosed in children.

The following prevalence rates were found in adults:

  • 11.5 % (men: 9.1 % women: 13.6 %) of adult people with ADHD compared to 1.4 % (men: 1.1 %; women: 1.7 %) of those not affected.54
  • 33.2 % in adult persons with ADHD37 to 80.3 % in adult outpatients with ADHD218
  • For non-affected persons: 0.6 %37
    = 50 times the risk

A meta-analysis found personality disorders:110

  • in the total population at
    • 0.31 % to 33.8 % of persons with ADHD vs. 0 % to 3.9 % of people without ADHD
  • in clinical cases with
    • 21.9 % to 65.95 % of persons with ADHD vs. 6.6 % to 34.4 % of people without ADHD

14.1. Antisocial PS - 18 % (vs. 2 to 3.5 %)

One study found antisocial personality disorder in 18% of people with ADHD-HI with hyperactivity compared to 2% of those without.219.
Other sources cite 37.1 %22087 .
One study found Antisocial PS in 18.9% of adult persons with ADHD compared to 3.5% of non-affected people at least once in their lifetime.62

Of 30 prison inmates with ADHD-HI, 96% also had antisocial personality disorder.
In contrast, 20 non-prison ADHD-HI affected people and 18 non-affected people (without ADHD) were not found to have Antisocial Personality Disorder.Interestingly, amphetamines are the drugs most commonly used by prison inmates affected by ADHD-HI.129 Amphetamines are known to be a highly effective medication for ADHD.

For domestic violence offenders who had ADHD, ADHD treatment reduced domestic violence far more significantly than domestic violence interventions.221

14.2. Borderline PS / emotionally unstable PS - 18 to 33 % (vs. 1 to 5 %)

Adults with ADHD are said to have BPD in 18.3% of cases222
A population study found that 33.7% of people with ADHD also had borderline personality disorder (BPD) (vs. 5.2% in the general population).62
A Swedish cohort study found a 19.4-fold risk of comorbid borderline personality disorder in people with ADHD.223 3.9% of the more than 2 million people studied had an ADHD diagnosis (women 3.0%, men 4.8%), 0.5% had BPD (women 0.8%, men 0.1%). People who had relatives with an ADHD diagnosis also had an increased risk of BPD:

  • Identical twins: n = 9,130, OR = 11.2 (Among 9,130 twins, the risk of BPD was 11.2 times higher if the other twin had ADHD)
  • Fraternal twins: N = 17,350, OR = 1.0
  • Full siblings: n = 2,211,396, OR = 2.4
  • Maternal half-siblings: n = 332,486, OR = 1.4
  • Half-siblings on the paternal side: n = 331,080; OR = 1.5
  • Cousins Parents Full siblings:n = 6,456,848; OR = 1.5
  • Cousins Maternal parents Half-siblings: n = 472,212; OR = 1.3
  • Cousins Paternal parents Half-siblings: n = 466,836; OR = 1.2

The risk of a BPD diagnosis if the person with ADHD had ADHD themselves or a full sibling was:223

  • 19.1 times higher in women (OR = 19.1)
  • 21.8 times higher in men (OR = 21.8)

People with ADHD in childhood were 14% more likely to be diagnosed with BPD later in life.224

BPD in people with ADHD: 35.7%22087

In adult psychiatric clinical patients with ADHD: 30.6 %69

People with ADHD have an ADHD prevalence of 30 to 60 %.225226227228

For the differential diagnosis of ADHD / Borderline, see Emotionally unstable personality / Borderline In the article Differential diagnostics for ADHD in the chapter Diagnostics.

14.3. Anxious PS - 10.6 % (vs. 2.1 %)

One study found avoidant PS in 10.6% of adult persons with ADHD compared to 2.1% of non-affected people at least once in their lifetime.62
In adult psychiatric clinical patients with ADHD: 31.6 %69

14.4. Self-insecure PS

27,1 %22087

14.5. Compulsive PS - 19.3 (vs. 7.8 %)

One study found compulsive PS in 19.3% of adult persons with ADHD compared to 7.8% of non-affected people at least once in their lifetime.62
40,7 %22087

In adult psychiatric clinical patients with ADHD: 10.2 %69

14.6. Combined PS

In adult psychiatric clinical patients with ADHD: 25.5 %69

14.7. Paranoid PS - 14.8 % (vs. 4.1 %)

20,0 %22087
One study found Paranoid PS in 14.8% of adult persons with ADHD compared to 4.1% of non-affected people at least once in their lifetime.62

14.8. Dependent PS - 3.1 % (vs. 0.4 %)

15,7 %22087
One study found Dependency PS in 3.1% of adult persons with ADHD compared to 0.4% of non-affected people at least once in their lifetime.62

In adult psychiatric clinical patients with ADHD: 18.4 %69

14.9. Narcissistic PS

15.7 %22087
One study found Narcissistic PS in 25.2% of adult persons with ADHD compared to 5.7% of non-affected people at least once in their lifetime.62

14.10. Histrionic PS - 10.7 % (vs. 1.6 %)

14,3 %22087
One study found Histrionic PS in 10.7% of adult persons with ADHD compared to 1.6% of non-affected people at least once in their lifetime.62

14.11. Schizotypal PS - 22.4 % (vs. 3.5 %)

8,6 %87
One study found Schizotypal PS in 22.4% of adult persons with ADHD compared to 3.5% of non-affected people at least once in their lifetime.62

Former names: Borderline schizophrenia, latent schizophrenic reaction, pseudoneurotic schizophrenia

14.12. Schizoid PS - 9.2 % (vs. 2.9 %)

6.4 %87
One study found schizoid PS in 9.2% of adult persons with ADHD compared to 2.9% of non-affected people at least once in their lifetime.62

15. Premenstrual dysphoric disorder (PMDD) - 31.4 % (vs. 9.8 %)

Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS). It occurs in the days before menstruation and subsides after it begins. Symptoms are

  • Mood swings
  • Irritability
  • Feelings of anxiety
  • Concentration difficulties
  • depressive moods.

PMDD was reported by 31.4% of women with a self-reported ADHD diagnosis and by 41.1% of women with a positive ADHD screening according to ASRS, compared to 9.8% of women without ADHD.229

16. Tic disorders 30 % (vs. 5 %)

Source618

About 30% of all patients with ADHD have tics or Tourette syndrome, while about half of all patients with a tic disorder or TS also have ADHD.230
The population prevalence of tic disorders is around 5%231

17. Post-traumatic stress disorder (PTSD) - 11.9% to 28% (vs. up to 3.3% to 6%)

  • The population prevalence of PTSD is
    • 3,3 %64
    • 6 % Lifetime prevalence62

The following prevalence values of comorbid PTSD were found in people with ADHD:

METASTUDY:

  • 28 to 36 % in adults with ADHD (meta-analysis, k = 21)232

Studies:

  • 0.7 % Adults with ADHD in total63
    • 0.7 % Women
    • 0.7 % Men
    • 0.9 % ADHD-I
    • 0.0 % ADHD-C
    • 2.5 % ADHD-HI
  • 11.9 %, i.e. around 3.6 times higher.64
  • 22% of adult people with ADHD62
  • 26.5 % In adult psychiatric clinical patients with ADHD69
  • Comorbidity of ADHD and PTSD occurred 32% more frequently in women than in men, but only in adults (meta-analysis, k = 13, n = 13,585233

PTSD is associated with a greatly increased risk of ADHD (up to + 153 %)

  • 2.53-fold risk of ADHD (+153%) in war veterans with previous PTSD234
  • 2.19-fold ADHD risk (+ 119%) in war veterans with existing PTSD234

18. Impulse control disorder, impulse control disorder (ICD) - 19.6 % (vs. 6.1 %)

  • The population prevalence of impulse control disorder (ICD) is 6.1%. People with ADHD have a prevalence of 19.6%, which is around 3.2 times higher.64
  • Total adults 2.6 %; women 2.9 %, men 3.7 %; ADHD-I 1.2 %, ADHD-C 5.0 %, ADHD-HI 12.5 %63

Impulse control disorders are characterized by a recurring, irresistible urge to perform certain actions that harm the person with ADHD or others and are often associated with feelings of guilt or shame, although they provide short-term relief.

  • Pathological gambling (gambling addiction)
  • Kleptomania (stealing)
  • Pyromania (arson)

19. Adjustment disorders - 18.9 % (vs. 3 %)

Adjustment disorders are described as reactions to a one-off or ongoing stressful life event.
Types of adjustment disorders are:

  • Short depressive reaction
  • Prolonged depressive reaction (up to 2 years)
  • Mixed anxiety and depressive reaction
  • With predominant impairment of other feelings
  • With predominant Disorder of social behavior
  • With mixed disorders of emotions and social behavior
  • With other predominantly mentioned symptoms

Prevalence in the presence of ADHD:

  • In adult people with ADHD: 18.9%37
  • For non-affected persons: 3.0 %37
    = 6 times the risk

20. Mental disability - 13 %

13 %102

21. Eating disorders - Loss of Control Eating Syndrome (LOC-ES) - 7.5 to 11.4 % (vs. 1.4 %)

12-fold increased risk in people with ADHD-HI.235236

A cohort study of Iranian children and adolescents found an increased prevalence of ADHD of 7.5% among people with ADHD.237

A very large study found the risk of bulimia or anorexia increased 18.3-fold with ADHD.238

Appetite disorders in adults with ADHD: 21 %

Disordered eating was 40% more common in adolescents with ADHD.239

22. Psychoses - 8.8 % (vs. 3 %)

One study found psychosis in 8.8% of adult persons with ADHD compared to 3% of non-affected people at least once in their lifetime.62

23. Epilepsy - 3.4 % (vs. 0.5 to 1 %)

A meta-analysis of 63 studies with N = 1,073,188 people from 17 countries found:240
People with ADHD had an ADHD prevalence of 22.3% (12.7% for the ADHD-I subtype).
People with ADHD had an epilepsy prevalence of 3.4%.
The prevalence of ADHD is greatly increased in drug-resistant epilepsy.241

One study found that 35% of adult people with ADHD also had ADHD.242
Epilepsy and ADHD have a genetic correlation (rg=0.18), which was even stronger for focal epilepsy (rg=0.23).243

In adults with psychogenic non-epileptic seizures (PNES), ADHD was found in 63.6%, while in adults with epileptic seizures (ES), ADHD was found in 27.8%.244

Some anti-seizure medications can cause or worsen ADHD symptoms as a side effect, while some ADHD medications can increase the risk of seizures.245

The prevalence of epilepsy in the general population is 0.5 to 1 %.
44.1% of people with ADHD have at least one other mental health diagnosis in their lifetime.243

24. Schizophrenia - 3.4 % (vs. 0.8 %)

Frequency of schizophrenia in ADHD:

  • 4.59-fold risk of schizophrenia with ADHD (meta-analysis, k = 12, n = 1.85 million)246
    • 5.09 times the risk of a psychotic Disorder
  • 4.74-fold risk of schizophrenia with ADHD diagnosed in childhood247
    • 3.5% of the people with ADHD who were examined also had ADHD F 90.0, i.e. ADHD with hyperactivity, without ADHD-I (which, however, does not seem to fit in any way with the other figures mentioned in this section)
  • A Norwegian cohort study found schizophrenia in 3.4 % (men: 4.2 % women: 2.5 %) of adult people with ADHD compared to 0.8 % (men: 0.9 %; women: 0.6 %) of those not affected.54
  • Another study found a schizophrenia prevalence in ADHD of 0.9% across the age range24
  • People with ADHD with an additional comorbidity had a 2.14-fold risk of schizophrenia compared to people with ADHD without an additional comorbidity248 The risk of schizophrenia increased further with the number of comorbidities. In particular, ASD, mental retardation, tic disorder, depression and bipolar disorder showed the strongest correlation. 73.8% of persons with ADHD who initially had no psychiatric comorbidities had other psychiatric disorders prior to the onset of schizophrenia.

The incidence of ADHD is significantly increased in schizophrenia.

  • Children and adolescents with schizophrenia
    • 17% to 57% have ADHD at the same time (meta-analysis, k = 5)249
  • Adults with schizophrenia
    • 10% to 47% have ADHD at the same time (meta-analysis, k = 5)249
  • 47% reported ADHD in childhood or adulthood250
  • 23% reported ADHD in childhood and adulthood250

25. Obsessive-compulsive disorder - 1.9 to 2.4 %

Obsessive-compulsive disorders are more common in adults with ADHD.6

  • Adults with ADHD overall: 1.9 %; women 1.4 %, men 2.4 %; ADHD-I 0.9 %, ADHD-C 1.5 %, ADHD-HI 12.5 %63
  • 2.4 % over the entire age range24
  • In a large study, the prevalence of ADHD was found to be 2.19 times higher in family members of people with ADHD.251
  • Of 70 adults with ADHD, 8.7% had OCD in their lifetime, compared to 5.7% of the 70 unaffected52

26. Intellectual disability - 1.4 %

Total adults 1.4 %; women 1.8 %, men 1.0 %; ADHD-I 1.2 %, ADHD-C 1.0 %, ADHD-HI 5.0 %63

27. Migraine

Source18

28. Obesity

2.1-fold risk for people with ADHD.252

ne study found that gene variants that correlate with obesity can causally increase the risk of ADHD.148
For treatment options, see below under 4.5.

29. Socialization disorder

Source6

30. Disorder of sexual development

Source6

  • Earlier onset of sexual activity
    • For children with people with ADHD: 15 years253
    • For non-affected persons: 16 years253
  • More sexual partners
    • For people with ADHD: 18.6253
    • For non-affected persons: 6.5253
  • Less time with a partner253
  • Higher rate of contraception253
  • High rate of unwanted pregnancies
    • In children with ADHD: 38 %253
    • For non-affected persons: 4 %253
      = 19.5 times the risk
  • Teenage pregnancies 5.5 times254
    • Teenage pregnancies of mothers with ADHD: 15.3%
    • Teenage pregnancies of mothers without ADHD: 2.8%
  • Birth rate increased (42:1)253
    = 42 times the risk
  • Higher risk of sexually transmitted diseases
    • For people with ADHD: 16 %253
    • For non-affected persons: 4 %253
      = 4 times the risk

31. Narcolepsy

A meta-analysis found that around 33% of people with narcolepsy also have ADHD.34

32. Messi syndrome / Hoarding

Messi syndrome is characterized by a strong urge to collect useless objects with a tendency to litter the living environment. A strong coincidence with ADHD is discussed.255 An overview of the literature can be found in Kuwano et al.256 They found a comorbidity of ADHD in 26.7% of people with ADHD.

In 71.6% of ADHD sufferers with comorbid hoarding, MPH improved the hoarding.257 In 5% it remained unchanged, 23.4% showed a slight worsening.

33. Attachment disorders

Source6

One study found that gene variants that correlate with increased social interaction are a protective factor against ADHD.148

34. Enuresis (enuresis)

Source6
Enuresis in children increased the risk of comorbid ADHD by 2.15-fold (OR 3.15).258

35. Encopresis (defecation)

Source6

36. Suicidal tendencies - 2.4 to 6.7-fold

A meta-analysis of 57 studies found a correlation between ADHD and259

  • Suicide attempts (OR 2.37)
  • Suicidal thoughts (OR 3.53)
  • Suicide plans (OR 4.54)
  • Suicide (OR 6.69).

According to the study, suicide is between 2.37 and 6.69 times more common in people with ADHD than in those without the disorder.

Another study found increased suicidality in children and adolescents with ADHD (OR 1.1), but this was mediated by comorbid depression, irritability and anxiety, not ADHD itself.260

37. Fibromyalgia - 4-fold

One study found a fourfold frequency of ADHD in people with fibromyalgia, without quantifying the frequency of fibromyalgia in people with ADHD.261

38. Dopamine transporter deficiency syndrome (DTDS)

Dopamine transporter deficiency syndrome (DTDS) is also known as infantile parkinsonism-dystonia.
Prevalence: very rare. To date, 60 people with ADHD are known.262

DTDS is a hereditary genetic disorder with a dysfunctional dopamine transporter.
The classic early-onset DTDS occurs within the first 6 months of life. Rarely, there is late-onset DTDS, which only becomes apparent in adolescence or adulthood.262263

In one study, all people with ADHD from early (infantile or juvenile) parkinsonism showed severely reduced DAT function (homozygous dysfunctional or two heterozygous dysfunctional DAT variants). The more severe the DAT deficiency, the earlier the onset of parkinsonism. Most of the people with ADHD showed previously unknown de novo variants. The dysfunctions were multifaceted: reduced dopamine binding affinity, reduced cell surface transporter, loss of post-translational dopamine transporter glycosylation and failure of amphetamine-mediated dopamine efflux.263 DTDS-DAT variants have been reported:

  • Homozygous
    • C.941C>T –> Ala314Val (3 of 8 persons with ADHD)
    • C.1269 + 1G>A –> unknown (2 of 8 persons with ADHD) another study also reported this variant264
    • C.1408_1409delinsAG –> Tyr470Ser (1 of 8 people with ADHD)
  • Combination of two dysfunctional DAT variants:
    • 1 out of 8 people with ADHD:
      • C.287-5_287-2delinsAAC –> unknown
      • C.1156G>A –> Gly386Arg
    • 1 out of 8 people with ADHD:
      • C.254G>T –> Arg85Leu
      • C.1333C>T –> Arg445Cys

Classic early-onset DTDS:262

  • Onset in the first 6 months (infants)
  • unspecific symptoms
    • Irritability
    • Difficulties with breastfeeding
    • axial hypotension
    • delayed motor development
  • consequences of a hyperkinetic movement disorder
    • with characteristics of
      • Chorea
      • Dystonia
      • Ballism
      • orolingual dyskinesia
  • In the course of time
    • Parkinsonism-dystonia complex
      • Bradykinesia, progressing to akinesia
      • dystonic posture
      • distal tremor
    • Rigidity
    • diminished facial expressions
    • severe motor delay due to restriction of voluntary movements
    • Episodic status dystonicus
    • Exacerbations of dystonia
    • secondary orthopaedic, gastrointestinal and respiratory complications
  • usually relative preservation of intelligence with good cognitive development

Atypical late-onset DTDS262

  • Onset in childhood to adulthood (4th decade of life)
    • in 5 of the 60 known people with ADHD
  • Infancy and toddlerhood:
    • Normal psychomotor development
  • Childhood
    • ADHD or individual ADHD symptoms
  • late onset
    • Parkinsonism dystonia with
      • Tremor
      • progressive bradykinesia
      • variable tone
      • dystonic posture

Diagnostics:262

Cerebrospinal fluid (CSF) almost always shows

  • HVA:5-HIAA ratio in SLC6A3-related DTDS is >4.0 (5.0-13.0) (normal range 1.0-4.0).
    • increased homovanillic acid levels (HVA, a metabolite derived from dopamine)
    • normal 5-hydroxyindoleacetic acid level (5-HIAA, a metabolite derived from serotonin)
  • Pterin normal
  • SPECT imaging using the ligand Ioflupane (DaTSCAN):
    • very abnormal results with absent/reduced tracer uptake in the basal ganglia
  • Genetic analysis
    • Presence of a heterozygous dominant-negative SLC6A3 pathogenic variant known to cause autosomal dominant DTDS
      • e.g. p.Lys619Asn

39. Stuttering

One study reports an ADHD prevalence of 50% in children and adolescents who stutter.265

40. Mental disorders in relatives of people with ADHD - 6.8-fold

An analysis of the entire Taiwanese population in 2010 examined 220,966 parents of children with ADHD-HI (according to ICD-9, which did not recognize ADHD-I), 174,460 siblings of children with ADHD-HI, and 5,875 children of parents with ADHD-HI. Among these relatives of people with ADHD-HI, the risk of severe psychiatric disorders was significantly increased compared to matched control subjects without relatives with ADHD-HI:266

  • ADHD-HI: 6.87-fold risk
  • Autism spectrum disorder: 4.14 times the risk
  • Bipolar disorders: 2.21 times the risk
  • Major depressive disorders: 2.08 times the risk
  • Schizophrenia: 1.69 times the risk

This can be understood as an indication of common genetic causes. However, it is also theoretically conceivable that this could be explained by the immunological consequences of (primarily viral) infections (which are more frequently transmitted between close relatives). See the chapter Immune system and behavior.
Similarly, similar external life circumstances and similar dysfunctional behavior patterns and stressful experiences are likely to be shared more frequently among close people. These mechanisms can complement each other.


  1. Schmidt, Waldmann, Petermann, Brähler (2010): Wie stark sind Erwachsene mit ADHS und komorbiden Störungen in ihrer gesundheitsbezogenen Lebensqualität beeinträchtigt? Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 58, 9–21, zitiert nach Schmidt, Petermann: ADHS über die Lebensspanne – Symptome und neue diagnostische Ansätze, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 59 (3), 2011, 227–238, Seite 229

  2. Merrill RM, Merrill AW, Madsen M (2022): Attention-Deficit Hyperactivity Disorder and Comorbid Mental Health Conditions Associated with Increased Risk of Injury. Psychiatry J. 2022 Oct 14;2022:2470973. doi: 10.1155/2022/2470973. PMID: 36277995; PMCID: PMC9586798.

  3. Okada T, Sotodate T, Ogasawara-Shimizu M, Nishigaki N (2024): Psychiatric comorbidities of attention deficit/hyperactivity disorder in Japan: a nationwide population-based study. Front Psychiatry. 2024 Oct 24;15:1359872. doi: 10.3389/fpsyt.2024.1359872. PMID: 39512898; PMCID: PMC11541049.

  4. nach Hudziak und Todd, 2001, zitiert aus Müller, Candrian, Kropotov (2011): ADHS – Neurodiagnostik in der Praxis, S. 16

  5. Rothenberger, Lauth, Ramacher-Faasen, Braun, Bock, von Aster, von Aster, von Aster in Lernen und Lernstörungen (2014), 3, pp. 185-202. DOI: 10.1024/2235-0977/a000071: Kommentare zu Romanos & Jans (2014). ADHS – an der Nahtstelle von Medizin und Pädagogik. Lernen und Lernstörungen, 3, 117 – 132; DOI: http://dx.doi.org/10.1024/2235-0977/a000071

  6. Edel, Vollmoeller: Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Erwachsenen, 2006, Seite 53, ohne %-Angabe

  7. Ohnishi T, Kobayashi H, Yajima T, Koyama T, Noguchi K (2019): Psychiatric Comorbidities in Adult Attention-deficit/Hyperactivity Disorder: Prevalence and Patterns in the Routine Clinical Setting. Innov Clin Neurosci. 2019 Sep 1;16(9-10):11-16. PMID: 32082943; PMCID: PMC7009330. n = 575

  8. Hollingdale, Woodhouse, Young, Fridman, Mandy (2019): Autistic spectrum disorder symptoms in children and adolescents with attention-deficit/hyperactivity disorder: a meta-analytical review. Psychol Med. 2019 Sep 18:1-14. doi: 10.1017/S0033291719002368.} METASTUDY}{{Joshi, Wilens (2022): Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder in Individuals with Autism Spectrum Disorder. Child Adolesc Psychiatr Clin N Am. 2022 Jul;31(3):449-468. doi: 10.1016/j.chc.2022.03.012. PMID: 35697395. REVIEW

  9. Russell G, Rodgers LR, Ukoumunne OC, Ford T (2014): Prevalence of parent-reported ASD and ADHD in the UK: findings from the Millennium Cohort Study. J Autism Dev Disord. 2014 Jan;44(1):31-40. doi: 10.1007/s10803-013-1849-0. PMID: 23719853.

  10. Jiang Z, Li G, Zeng S, Li J, Li Y, Lin J, Fan Q (2024): Causal Relationship between Attention-Deficit Hyperactivity Disorder and Autism Spectrum Disorder: A Two-Sample Mendelian Randomization. Br J Hosp Med (Lond). 2024 Dec 30;85(12):1-16. doi: 10.12968/hmed.2024.0588. Epub 2024 Dec 27. PMID: 39831504.

  11. Grzadzinski R, Di Martino A, Brady E, Mairena MA, O’Neale M, Petkova E, Lord C, Castellanos FX (2011): Examining autistic traits in children with ADHD: does the autism spectrum extend to ADHD? J Autism Dev Disord. 2011 Sep;41(9):1178-91. doi: 10.1007/s10803-010-1135-3. PMID: 21108041; PMCID: PMC3123401.

  12. Joshi G, DiSalvo M, Faraone SV, Wozniak J, Fried R, Galdo M, Belser A, Hoskova B, Dallenbach NT, De Leon MF, Biederman J (2020): Predictive utility of autistic traits in youth with ADHD: a controlled 10-year longitudinal follow-up study. Eur Child Adolesc Psychiatry. 2020 Jun;29(6):791-801. doi: 10.1007/s00787-019-01384-8. PMID: 31468149.

  13. Biederman J, Petty CR, Fried R, Wozniak J, Micco JA, Henin A, Doyle R, Joshi G, Galdo M, Kotarski M, Caruso J, Yorks D, Faraone SV (2010): Child behavior checklist clinical scales discriminate referred youth with autism spectrum disorder: a preliminary study. J Dev Behav Pediatr. 2010 Jul-Aug;31(6):485-90. doi: 10.1097/DBP.0b013e3181e56ddd. PMID: 20585266.

  14. Kotte A, Joshi G, Fried R, Uchida M, Spencer A, Woodworth KY, Kenworthy T, Faraone SV, Biederman J (2013): Autistic traits in children with and without ADHD. Pediatrics. 2013 Sep;132(3):e612-22. doi: 10.1542/peds.2012-3947. PMID: 23979086; PMCID: PMC3876754. n = 469

  15. Mulligan A, Anney RJ, O’Regan M, Chen W, Butler L, Fitzgerald M, Buitelaar J, Steinhausen HC, Rothenberger A, Minderaa R, Nijmeijer J, Hoekstra PJ, Oades RD, Roeyers H, Buschgens C, Christiansen H, Franke B, Gabriels I, Hartman C, Kuntsi J, Marco R, Meidad S, Mueller U, Psychogiou L, Rommelse N, Thompson M, Uebel H, Banaschewski T, Ebstein R, Eisenberg J, Manor I, Miranda A, Mulas F, Sergeant J, Sonuga-Barke E, Asherson P, Faraone SV, Gill M (2009): Autism symptoms in Attention-Deficit/Hyperactivity Disorder: a familial trait which correlates with conduct, oppositional defiant, language and motor disorders. J Autism Dev Disord. 2009 Feb;39(2):197-209. doi: 10.1007/s10803-008-0621-3. PMID: 18642069. n = 2.020

  16. Ohnishi T, Kobayashi H, Yajima T, Koyama T, Noguchi K (2019): Psychiatric Comorbidities in Adult Attention-deficit/Hyperactivity Disorder: Prevalence and Patterns in the Routine Clinical Setting. Innov Clin Neurosci. 2019 Sep 1;16(9-10):11-16. PMID: 32082943; PMCID: PMC7009330.

  17. Castellanos, Tannock (2002): Neuroscience of attention-deficit/hyperactivity disorder: the search for endophenotypes. Nat Rev Neurosci. 2002 Aug;3(8):617-28.; PMID: 12154363 DOI: 10.1038/nrn896, S. 619

  18. Strehl et al. (2013): Neurofeedback, Kohlhammer

  19. Gadow KD, DeVincent CJ, Pomeroy J (2006): ADHD symptom subtypes in children with pervasive developmental disorder. J Autism Dev Disord. 2006 Feb;36(2):271-83. doi: 10.1007/s10803-005-0060-3. PMID: 16477513.

  20. Joshi, Wilens (2022): Pharmacotherapy of Attention-Deficit/Hyperactivity Disorder in Individuals with Autism Spectrum Disorder. Child Adolesc Psychiatr Clin N Am. 2022 Jul;31(3):449-468. doi: 10.1016/j.chc.2022.03.012. PMID: 35697395. REVIEW

  21. Lee DO, Ousley OY (2006): Attention-deficit hyperactivity disorder symptoms in a clinic sample of children and adolescents with pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2006 Dec;16(6):737-46. doi: 10.1089/cap.2006.16.737. PMID: 17201617. n = 83

  22. Lee J, Lee SI (2023):Unrecognized comorbid autism spectrum disorder in children initially diagnosed with only attention deficit hyperactivity disorder. Asian J Psychiatr. 2023 Jul;85:103629. doi: 10.1016/j.ajp.2023.103629. PMID: 37243986.

  23. Mohammadi, Ahmadi, Khaleghi, Zarafshan, Mostafavi, Kamali, Rahgozar, Ahmadi, Hooshyari, Alavi, Shakiba, Salmanian, Molavi, Sarraf, Hojjat, Mohammadzadeh, Amiri, Arman, Ghanizadeh (2019): Prevalence of Autism and its Comorbidities and the Relationship with Maternal Psychopathology: A National Population-Based Study. Arch Iran Med. 2019 Oct 1;22(10):546-553.

  24. Merrill RM, Merrill AW, Madsen M (2022): Attention-Deficit Hyperactivity Disorder and Comorbid Mental Health Conditions Associated with Increased Risk of Injury. Psychiatry J. 2022 Oct 14;2022:2470973. doi: 10.1155/2022/2470973. PMID: 36277995; PMCID: PMC9586798. n = 382.488

  25. Lundström, Mårland, Kuja-Halkola, Anckarsäter, Lichtenstein, Gillberg, Nilsson (2019): Assessing autism in females: The importance of a sex-specific comparison. Psychiatry Res. 2019 Sep 13:112566. doi: 10.1016/j.psychres.2019.112566. n = 30.392

  26. Autism and Developmental Disabilities Monitoring Network Surveillance Year 2008 Principal Investigators; Centers for Disease Control and Prevention. Prevalence of autism spectrum disorders–Autism and Developmental Disabilities Monitoring Network, 14 sites, United States, 2008. MMWR Surveill Summ. 2012 Mar 30;61(3):1-19. PMID: 22456193.

  27. Panagiotidi, Overton, Stafford (2017): Co-Occurrence of ASD and ADHD Traits in an Adult Population.J Atten Disord. 2017 Aug 1:1087054717720720. doi: 10.1177/1087054717720720; n = 334

  28. Hara (2019): [Chronic Activation of the Dopaminergic Neuronal Pathway Improves Behavioral Abnormalities in the Prenatal Valproic Acid Exposure Mouse Model of Autism Spectrum Disorder]. [Article in Japanese] Yakugaku Zasshi. 2019;139(11):1391-1396. doi: 10.1248/yakushi.19-00131.

  29. Kaye AD, Allen KE, Smith Iii VS, Tong VT, Mire VE, Nguyen H, Lee Z, Kouri M, Jean Baptiste C, Mosieri CN, Kaye AM, Varrassi G, Shekoohi S (2024): Emerging Treatments and Therapies for Autism Spectrum Disorder: A Narrative Review. Cureus. 2024 Jul 2;16(7):e63671. doi: 10.7759/cureus.63671. PMID: 39092332; PMCID: PMC11293483. REVIEW

  30. ADHS, iPads, Schlaf und Konzentrationsprobleme: Im Licht neuer Erkenntnisse

  31. Sung, Hiscock, Sciberras, Efron (2008): Sleep problems in children with attention-deficit/hyperactivity disorder: prevalence and the effect on the child and family; Arch Pediatr Adolesc Med. 2008 Apr;162(4):336-42. doi: 10.1001/archpedi.162.4.336. n = 239

  32. Kostanecka-Endress, Woerner, Hajak, Rothenberger (2008): Tag und Nacht in Bewegung – Schlafverhalten hypermotorischer Kinder Tourette-Syndrom und hyperkinetisches Syndrom; Monatsschrift Kinderheilkunde; December 2000, Volume 148, Issue 12, pp 1113–1128; zitiert nach Steinhausen, Rothenberger, Döpfner (Herausgeber) (2010): Handbuch ADHS; Grundlagen, Klinik, Therapie und Verlauf der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung, Kohlhammer, Seite 187

  33. Schlüter, Buschatz, Kahlen, Dieffenbach, Trowitzsch (1999): Polysomnographie bei aufmerksamkeitsgestörten und hyperaktiven Kindern (Attention Deficit Hyperactivity Disorder, ADHD); Somnologie – Schlafforschung und Schlafmedizin, May 1999, Volume 3, Issue 3, pp 140–147

  34. Kim, Lee, Sung, Jung, Pak (2019): Prevalence of attention deficit hyperactivity disorder symptoms in narcolepsy: a systematic review. Sleep Med. 2019 Aug 3;65:84-88. doi: 10.1016/j.sleep.2019.07.022.

  35. Nishino, Sakai (2016): Modulations of Ventral Tegmental Area (VTA) Dopaminergic Neurons by Hypocretins/Orexins: Implications in Vigilance and Behavioral Control In: Monti, Pandi-Perumal, Chokroverty (Herausgeber) (2016): Dopamine and Sleep: Molecular, Functional, and Clinical Aspects, 65-90, 75

  36. Kooij (2019): ADHD and Sleep Webinar

  37. Oehler (2009), Vortrag beim 4. ADHS-Gipfel in Hamburg, 06.-08.02.2009 mit Verweis auf Schlander, Schwarz, Trott, Viapiano, Bonauer (2007): Who cares for patients with attention-deficit/hyperactivity disorder (ADHD)? Insights from Nordbaden (Germany) on administrative prevalence and physician involvement in health care provision; N.Eur Child Adolesc Psychiatry. 2007 Oct;16(7):430-8.

  38. Müller, Candrian, Kropotov (2011): ADHS – Neurodiagnostik in der Praxis, S. 17

  39. Prävalenz von Schlafstörungen unter Erwerbstätigen in Deutschland nach Geschlecht und Altersgruppe im Jahr 2008, Statista

  40. Shen, Li, Xue, Li, Li, Jiang, Sheng, Wang (2022): Nutritional complexity in children with ADHD related morbidities in China: A cross-sectional study. Asia Pac J Clin Nutr. 2022 Mar;31(1):108-117. doi: 10.6133/apjcn.202203_31(1).0012. PMID: 35357109.

  41. http://www.adhspedia.de/wiki/Fehldiagnosen

  42. Edel, Vollmoeller: Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Erwachsenen, Springer, 2006, Seite 40, unter Bezug auf Krause et al. 1998.

  43. Leitlinie der Arbeitsgemeinschaft ADHS der Kinder- und Jugendärzte e.V., Stand 2014

  44. https://www.klinikum.uni-heidelberg.de/AG-Anaesthesie-und-Schlafapnoe.114157.0.html, nicht mehr online

  45. Smith, Gozal, Hunter, Kheirandish-Gozal (2017): Parent-Reported Behavioral and Psychiatric Problems Mediate the Relationship between Sleep-Disordered Breathing and Cognitive Deficits in School-Aged Children. Front Neurol. 2017 Aug 11;8:410. doi: 10.3389/fneur.2017.00410. eCollection 2017.

  46. Hudgins (2003): Experiential Treatment for PTSD. New York, NY: Springer Publishing Company, zitiert nach Böhm (2010/2012): Erfahrungen mit “SynestheticProcessing”/emoflex©; Heft 4/2010 „neuenAkzente“ des ADHS Deutschland e.V.

  47. Tempesta, Couyoumdjian, Curcio, Moroni, Marzano, De Gennaro, Ferrara (2010): Lack of sleep affects the evaluation of emotional stimuli. BrainRes Bull, n = 40

  48. Böhm (2010/2012): Erfahrungen mit “SynestheticProcessing”/emoflex©; Heft 4/2010 „neuenAkzente“ des ADHS Deutschland e.V.

  49. Kooij, Huss, Asherson, Akehurst, Beusterien, French, Sasané, Hodgkins (2012): Distinguishing comorbidity and successful management of adult ADHD. J Atten Disord. 2012 Jul;16(5 Suppl):3S-19S. doi: 10.1177/1087054711435361.

  50. Parikh AK, Musolff N, Tchack M, Rao B (2025): A Case-Control Study of Trichotillomania Patients Using a National Database. Skin Appendage Disord. 2025 Aug;11(4):379-384. doi: 10.1159/000543503. PMID: 40771450; PMCID: PMC12324719.

  51. Ghanizadeh A (2008): Association of nail biting and psychiatric disorders in children and their parents in a psychiatrically referred sample of children. Child Adolesc Psychiatry Ment Health. 2008 Jun 2;2(1):13. doi: 10.1186/1753-2000-2-13. PMID: 18513452; PMCID: PMC2435519. n = 450

  52. Sobanski E, Brüggemann D, Alm B, Kern S, Deschner M, Schubert T, Philipsen A, Rietschel M (2007): Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci. 2007 Oct;257(7):371-7. doi: 10.1007/s00406-007-0712-8. PMID: 17902010. n = 140

  53. Chen, Hartman, Haavik, Harro, Klungsøyr, Hegvik, Wanders, Ottosen, Dalsgaard, Faraone, Larsson (2018): Common psychiatric and metabolic comorbidity of adult attention-deficit/hyperactivity disorder: A population-based cross-sectional study. PLoS One. 2018 Sep 26;13(9):e0204516. doi: 10.1371/journal.pone.0204516. PMID: 30256837; PMCID: PMC6157884. n = 5.551.807, 18 bis 64 Jahre

  54. Solberg BS, Halmøy A, Engeland A, Igland J, Haavik J, Klungsøyr K (2018): Gender differences in psychiatric comorbidity: a population-based study of 40 000 adults with attention deficit hyperactivity disorder. Acta Psychiatr Scand. 2018 Mar;137(3):176-186. doi: 10.1111/acps.12845. PMID: 29266167; PMCID: PMC5838558.

  55. Roy, Oldehinkel, Verhulst; Ormel, Hartman (2014): Anxiety and disruptive behavior mediate pathways from attention-deficit/hyperactivity disorder to depression; J Clin Psychiatry. 2014 Feb;75(2):e108-13. doi: 10.4088/JCP.13m08648.; n = 1584

  56. Schlander, Schwarz, Trott, Viapiano, Bonauer (2007): Who cares for patients with attention-deficit/hyperactivity disorder (ADHD)? Insights from Nordbaden (Germany) on administrative prevalence and physician involvement in health care provision; N.Eur Child Adolesc Psychiatry. 2007 Oct;16(7):430-8., zitiert nach Oehler (2009), Vortrag beim 4. ADHS-Gipfel in Hamburg, 06.-08.02.2009

  57. Adzrago D, Sulley S, Williams F (2025): Mental health in children with and without ADHD: the role of physical activity and parental nativity. Child Adolesc Psychiatry Ment Health. 2025 Jan 18;19(1):2. doi: 10.1186/s13034-025-00859-8. PMID: 39827157; PMCID: PMC11743031.

  58. Häufigkeit der Komorbidität bei Kindern mit ADHS nach Hudziak und Todd, 2001, zitiert aus Müller, Candrian, Kropotov (2011): ADHS – Neurodiagnostik in der Praxis, S. 16

  59. adhs-chaoten; Thread: ADS / ADHS und saisonale Depression / Winterdepression

  60. Philipsen, Heßlinger, Tebartz van Elst: AufmerksamkeitsdefizitHyperaktivitätsstörung im Erwachsenenalter – Diagnostik, Ätiologie und Therapie (ÜBERSICHTSARBEIT), Deutsches Ärzteblatt, Jg. 105, Heft 17, 25. April 2008, Seite 311 – 317, 313 , Seite 313 unter Verweis auf Rösler, Heßlinger, Philipsen (2007): ADHS im Erwachsenenalter. In: Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkrankungen – State of the Art. 2. Auflage. München: Urban & Fischer, 2007

  61. Faraone, APA 2006: Massachusetts General Hospital Study, zitiert nach Oehler (2009), Vortrag beim 4. ADHS-Gipfel in Hamburg, 06.-08.02.2009

  62. Bernardi S, Faraone SV, Cortese S, Kerridge BT, Pallanti S, Wang S, Blanco C (2012): The lifetime impact of attention deficit hyperactivity disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). Psychol Med. 2012 Apr;42(4):875-87. doi: 10.1017/S003329171100153X. PMID: 21846424; PMCID: PMC3383088. n = 34.000

  63. Ohnishi, Kobayashi, Yajima, Koyama, Noguchi (2020): Psychiatric Comorbidities in Adult Attention-deficit/Hyperactivity Disorder: Prevalence and Patterns in the Routine Clinical Setting. Innov Clin Neurosci. 2019 Sep 1;16(9-10):11-16. PMID: 32082943; PMCID: PMC7009330. n = 575

  64. Endrass, G (2024): ADHS aktuell – Mythen und Bedenken versus Fakten; NeuroTransmitter 2024; 35 (1-2)

  65. Choi WS, Woo YS, Wang SM, Lim HK, Bahk WM (2022): The prevalence of psychiatric comorbidities in adult ADHD compared with non-ADHD populations: A systematic literature review. PLoS One. 2022 Nov 4;17(11):e0277175. doi: 10.1371/journal.pone.0277175. PMID: 36331985; PMCID: PMC9635752.

  66. Lundin C, Wikman A, Wikman P, Kallner HK, Sundström-Poromaa I, Skoglund C (2023): Hormonal Contraceptive Use and Risk of Depression Among Young Women With Attention-Deficit/Hyperactivity Disorder. J Am Acad Child Adolesc Psychiatry. 2023 Jun;62(6):665-674. doi: 10.1016/j.jaac.2022.07.847. PMID: 36332846. n = 792.913

  67. Orsolini L, Longo G, Volgare R, Piergentili S, Servasi M, Perugi G, Volpe U (2024): Cyclothymic affective temperament and low positive attitude coping strategies as predictors of comorbid depressive symptomatology in adult ADHD patients. J Affect Disord. 2024 Nov 15;365:417-426. doi: 10.1016/j.jad.2024.08.083. PMID: 39154981.

  68. Callovini T, Di Nicola M, Pepe M, Crocamo C, Bartoli F, Sani G, Carrà G (2024): Influence of temperament and emotional dysregulation on depressive symptoms in adults with attention-deficit/hyperactivity disorder: A structural equation modelling analysis. J Psychiatr Res. 2024 Dec;180:227-233. doi: 10.1016/j.jpsychires.2024.10.019. PMID: 39454489.

  69. Miesch, Deister (2018): Die Aufmerksamkeitsdefizit- und Hyperaktivitätsstörung (ADHS) in der Erwachsenenpsychiatrie: Erfassung der ADHS-12-Monatsprävalenz, der Risikofaktoren und Komorbidität bei ADHS; Attention-deficit/hyperactivity disorder (ADHD) in adult psychiatry: Data on 12-month prevalence, risk factors and comorbidity; Fortschr Neurol Psychiatr. 2018 Feb 28. doi: 10.1055/s-0043-119987. DOI: 10.1055/s-0043-119987, n = 166

  70. Chang KD, Steiner H, Ketter TA (2000): Psychiatric phenomenology of child and adolescent bipolar offspring. J Am Acad Child Adolesc Psychiatry. 2000 Apr;39(4):453-60. doi: 10.1097/00004583-200004000-00014. PMID: 10761347.

  71. Avinoam R, Revital R, Doron B, Ella S, Yaacov B (2025): A Common Cause of ADHD and Bipolar Disorder (BD). Bipolar Disord. 2025 Sep;27(6):472-475. doi: 10.1111/bdi.70057. PMID: 40891025; PMCID: PMC12483310.

  72. Steinhausen, Rothenberger, Döpfner (Herausgeber) (2020): Handbuch ADHS; Grundlagen, Klinik, Therapie und Verlauf der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung, Seite 204

  73. Pranjić M, Rahman N, Kamenetskiy A, Mulligan K, Pihl S, Arnett AB (2023): A systematic review of behavioral and neurobiological profiles associated with coexisting attention-deficit/hyperactivity disorder and developmental coordination disorder. Neurosci Biobehav Rev. 2023 Sep 12;153:105389. doi: 10.1016/j.neubiorev.2023.105389. PMID: 37704094. REVIEW

  74. Meachon EJ, Schaider JP, Alpers GW (2025): Motor skills in children with ADHD: overlap with developmental coordination disorder. BMC Psychol. 2025 Jan 18;13(1):53. doi: 10.1186/s40359-024-02282-8. PMID: 39827182; PMCID: PMC11742537.

  75. Fliers E, Rommelse N, Vermeulen SH, Altink M, Buschgens CJ, Faraone SV, Sergeant JA, Franke B, Buitelaar JK (2008): Motor coordination problems in children and adolescents with ADHD rated by parents and teachers: effects of age and gender. J Neural Transm (Vienna). 2008;115(2):211-20. doi: 10.1007/s00702-007-0827-0. PMID: 17994185. n = 755

  76. Fortnum K, Bourke M, Kwan M, O’Flaherty M, Dowling SK, Cairney J (2025): Comorbid Developmental Coordination Disorder and ADHD: The Effects on Emotional and Behavioural Problems in Young Children. Child Psychiatry Hum Dev. 2025 May 16. doi: 10.1007/s10578-025-01858-8. PMID: 40377831.

  77. Yasunaga M, Higuchi R, Kusunoki K, Mochizuki N (2025): Associations Among Developmental Coordination Disorder Traits, Neurodevelopmental Difficulties and University Personality Inventory Scores in Undergraduate Students at a Japanese National University: A Cross-Sectional Correlational Study. Brain Sci. 2025 Aug 21;15(8):895. doi: 10.3390/brainsci15080895. PMID: 40867226; PMCID: PMC12384660.

  78. Zentrales ADHS-Netz: Allgemeine Infos zu ADHS; “Welche weiteren komorbiden Probleme gibt es?”

  79. Gnanavel, Sharma, Kaushal, Hussain (2019): Attention deficit hyperactivity disorder and comorbidity: A review of literature. World J Clin Cases. 2019 Sep 6;7(17):2420-2426. doi: 10.12998/wjcc.v7.i17.2420.

  80. Biederman J (2005): Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry. 2005 Jun 1;57(11):1215-20. doi: 10.1016/j.biopsych.2004.10.020. PMID: 15949990. REVIEW

  81. Müller, Candrian, Kropotov (2011): ADHS – Neurodiagnostik in der Praxis, mit Verweis auf Hudziak, Todd 2001

  82. Mohammadi, Zarafshan, Khaleghi, Ahmadi, Hooshyari, Mostafavi, Ahmadi, Alavi, Shakiba, Salmanian (2019): Prevalence of ADHD and Its Comorbidities in a Population-Based Sample. J Atten Disord. 2019 Dec 13:1087054719886372. doi: 10.1177/1087054719886372. n = 30.532

  83. Sagar-Ouriaghli, Milavic, Barton, Heaney, Fiori, Lievesley, Singh, Santosh (2018): Comparing the DSM-5 construct of Disruptive Mood Dysregulation Disorder and ICD-10 Mixed Disorder of Emotion and Conduct in the UK Longitudinal Assessment of Manic Symptoms (UK-LAMS) Study. Eur Child Adolesc Psychiatry. 2018 Sep;27(9):1095-1104. doi: 10.1007/s00787-018-1149-5.

  84. Kain, Landerl, Kaufmann (2008): Komorbidität bei ADHS. Monatsschrift Kinderheilkunde,156, 757 – 767, zitiert nach Rothenberger, Lauth, Ramacher-Faasen, Braun, Bock, von Aster, von Aster, von Aster in Lernen und Lernstörungen (2014), 3, pp. 185-202. DOI: 10.1024/2235-0977/a000071: Kommentare zu Romanos & Jans (2014). ADHS – an der Nahtstelle von Medizin und Pädagogik. Lernen und Lernstörungen, 3, 117 – 132; DOI: http://dx.doi.org/10.1024/2235-0977/a000071

  85. Schmidt, S., Waldmann, H.-C., Petermann, F. & Brähler, E. (2010). Wie stark sind Erwachsene mit ADHS und komorbiden Störungen in ihrer gesundheitsbezogenen Lebensqualität beeinträchtigt? Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 58, 9–21, zitiert nach Schmidt, Petermann: ADHS über die Lebensspanne – Symptome und neue diagnostische Ansätze, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 59 (3), 2011, 227–238, Seite 229

  86. Schlander, Schwarz, Trott, Viapiano, Bonauer (2007): Who cares for patients with attention-deficit/hyperactivity disorder (ADHD)? Insights from Nordbaden (Germany) on administrative prevalence and physician involvement in health care provision; N.Eur Child Adolesc Psychiatry. 2007 Oct;16(7):430-8.

  87. Oehler (2009), Vortrag beim 4. ADHS-Gipfel in Hamburg, 06.-08.02.2009

  88. Schmidt, Petermann: ADHS über die Lebensspanne – Symptome und neue diagnostische Ansätze, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 59 (3), 2011, 227–238

  89. Mayes SD, Pardej SK, Waschbusch DA (2024): Oppositional Defiant Disorder in Autism and ADHD. J Autism Dev Disord. 2024 Jul 27. doi: 10.1007/s10803-024-06437-9. PMID: 39066970. n = 2.400

  90. Schlander, Schwarz, Trott, Viapiano, Bonauer (2007): Who cares for patients with attention-deficit/hyperactvity disorder (ADHD)? Insights from Nordbaden (Germany) on administrative prevalence and physician involvement in health care provision; N.Eur Child Adolesc Psychiatry. 2007 Oct;16(7):430-8.

  91. Hudziak und Todd, 2001, zitiert aus Müller, Candrian, Kropotov (2011): ADHS – Neurodiagnostik in der Praxis, S. 16

  92. Steinhausen, Rothenberger, Döpfner (Herausgeber) (2010): Handbuch ADHS; Grundlagen, Klinik, Therapie und Verlauf der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung, Kohlhammer, Seite 173

  93. Masi, Manfredi, Nieri, Muratori, Pfanner, Milone (2017): A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression. J Clin Psychopharmacol. 2017 Aug 10. doi: 10.1097/JCP.0000000000000747; n = 40

  94. Sonuga-Barke, Bitsakou, Thompson (2010): Beyond the dual pathway model: Evidence for the dissociation of timing, inhibitory and delay-related impairments in Attention Deficit/Hyperactivity Disorder.

  95. Witthöft, Koglin, Petermann (2010): Zur Komorbidität von aggressivem Verhalten und ADHS. Kindheit und Entwicklung, 19, 218–227, zitiert nach Schmidt, Petermann: ADHS über die Lebensspanne – Symptome und neue diagnostische Ansätze, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 59 (3), 2011, 227–238, Seite 232

  96. Salmanian, Mohammadi, Hooshyari, Mostafavi, Zarafshan, Khaleghi, Ahmadi, Alavi, Shakiba, Rahgozar, Safavi, Arman, Delpisheh, Mohammadzadeh, Hosseini, Ostovar, Hojjat, Armani, Talepasand, Amiri (2019): Prevalence, comorbidities, and sociodemographic predictors of conduct disorder: the national epidemiology of Iranian children and adolescents psychiatric disorders (IRCAP). Eur Child Adolesc Psychiatry. 2019 Dec 6. doi: 10.1007/s00787-019-01448-9.

  97. Shankman, Lewinsohn, Klein, Small, Seeley, Altman (2009): Subthreshold conditions as precursors for full syndrome disorders: A 15-year longitudinal study of multiple diagnostic classes. Journal of Child Psychology and Psychiatry, 50, 1485–1494, zitiert nach Schmidt, Petermann: ADHS über die Lebensspanne – Symptome und neue diagnostische Ansätze, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 59 (3), 2011, 227–238, Seite 232

  98. Vuksanovic (2013): Die Aktivität der Hpothalamus-Hypophysen-Nebennierenrinden-Achse bei Aufmerksamkeits-Defizit und Hyperaktivitäts-Störung, Dissertation, Seite 102, 114

  99. Beesdo K, Knappe S, Pine DS (2009): Anxiety and anxiety disorders in children and adolescents: developmental issues and implications for DSM-V. Psychiatr Clin North Am. 2009 Sep;32(3):483-524. doi: 10.1016/j.psc.2009.06.002. PMID: 19716988; PMCID: PMC3018839. REVIEW

  100. Strawn JR, Geracioti L, Rajdev N, Clemenza K, Levine A (2018): Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients: an evidence-based treatment review. Expert Opin Pharmacother. 2018 Jul;19(10):1057-1070. doi: 10.1080/14656566.2018.1491966. PMID: 30056792; PMCID: PMC6340395. REVIEW

  101. Deng X, Ren H, Wu S, Jie H, Gu C (2024): Exploring the genetic and socioeconomic interplay between ADHD and anxiety disorders using Mendelian randomization. Front Psychiatry. 2024 Aug 6;15:1439474. doi: 10.3389/fpsyt.2024.1439474. PMID: 39165506; PMCID: PMC11333326.

  102. Steinhausen, Rothenberger, Döpfner (Herausgeber) (2010): Handbuch ADHS; Grundlagen, Klinik, Therapie und Verlauf der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung, Kohlhammer, Seite 174

  103. D’Agati, Curatolo, Mazzone (2019): Comorbidity between ADHD and anxiety disorders across the lifespan. Int J Psychiatry Clin Pract. 2019 Jun 24:1-7. doi: 10.1080/13651501.2019.1628277.

  104. Edel, Vollmoeller: Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Erwachsenen, 2006, Seite 53

  105. Wancata, Freidl, Fabrian (2011): Epidemiologie der Angststörungen, Journal für Neurologie Neurochirurgie und Psychiatrie, 2011; 12 (4), 332-335

  106. Murray, Caye, McKenzie, Auyeung, Murray, Ribeaud, Freeston, Eisner (2020): Reciprocal Developmental Relations Between ADHD and Anxiety in Adolescence: A Within-Person Longitudinal Analysis of Commonly Co-Occurring Symptoms. J Atten Disord. 2020 Mar 14:1087054720908333. doi: 10.1177/1087054720908333. PMID: 32172640.

  107. Fuller-Thomson, Carrique, MacNeil (2021): Generalized anxiety disorder among adults with attention deficit hyperactivity disorder. J Affect Disord. 2021 Nov 16:S0165-0327(21)01096-X. doi: 10.1016/j.jad.2021.10.020. PMID: 34799150. n = 6.989

  108. Wang F, Yang H, Li F, Zheng Y, Xu H, Wang R, Li Y, Cui Y (2024): Prevalence and comorbidity of anxiety disorder in school-attending children and adolescents aged 6-16 years in China. BMJ Paediatr Open. 2024 Mar 27;8(1):e001967. doi: 10.1136/bmjpo-2023-001967. PMID: 38538104; PMCID: PMC10982779.

  109. Solberg BS, Halmøy A, Engeland A, Igland J, Haavik J, Klungsøyr K (2018): Gender differences in psychiatric comorbidity: a population-based study of 40 000 adults with attention deficit hyperactivity disorder. Acta Psychiatr Scand. 2018 Mar;137(3):176-186. doi: 10.1111/acps.12845. PMID: 29266167; PMCID: PMC5838558. n = 40.000

  110. Choi WS, Woo YS, Wang SM, Lim HK, Bahk WM (2022): The prevalence of psychiatric comorbidities in adult ADHD compared with non-ADHD populations: A systematic literature review. PLoS One. 2022 Nov 4;17(11):e0277175. doi: 10.1371/journal.pone.0277175. PMID: 36331985; PMCID: PMC9635752. METASTUDIE

  111. Hernández M, Levin FR, Campbell ANC (2025): ADHD and Alcohol Use Disorder: Optimizing Screening and Treatment in Co-occurring Conditions. CNS Drugs. 2025 May;39(5):457-472. doi: 10.1007/s40263-025-01168-6. PMID: 39979544. REVIEW

  112. McMahon C, Schweinle W, Anand V (2024): Substance Use Disorder in Adults with ADHD in South Dakota. S D Med. 2024 Aug;77(8):342-348. PMID: 39311728.

  113. Koura S, White A, Masdon J, Brewer KL, Parker-Cote JL, Meggs WJ (2023): Retrospective chart review of substance abuse in patients with psychiatric emergencies in an emerging urban county. J Am Coll Emerg Physicians Open. 2023 Aug 17;4(4):e13028. doi: 10.1002/emp2.13028. PMID: 37600902; PMCID: PMC10435894.

  114. Solberg BS, Halmøy A, Engeland A, Igland J, Haavik J, Klungsøyr K (2018): Gender differences in psychiatric comorbidity: a population-based study of 40 000 adults with attention deficit hyperactivity disorder. Acta Psychiatr Scand. 2018 Mar;137(3):176-186. doi: 10.1111/acps.12845. PMID: 29266167; PMCID: PMC5838558. n = 1.701.206

  115. Md Yusop MR, Mohamed S, Jaris NH, Jamal A (2024): Factors associated with attention deficit hyperactivity disorder symptoms among patients with substance use in Malaysia. East Asian Arch Psychiatry. 2024 Dec;34(4):91-102. doi: 10.12809/eaap2426. PMID: 39743482.

  116. Lastres-Becker I, Cebeira M, de Ceballos ML, Zeng BY, Jenner P, Ramos JA, Fernández-Ruiz JJ (2001): Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson’s syndrome and of MPTP-treated marmosets. Eur J Neurosci. 2001 Dec;14(11):1827-32. doi: 10.1046/j.0953-816x.2001.01812.x. PMID: 11860478.

  117. Mailleux P, Vanderhaeghen JJ (1993): Dopaminergic regulation of cannabinoid receptor mRNA levels in the rat caudate-putamen: an in situ hybridization study. J Neurochem. 1993 Nov;61(5):1705-12. doi: 10.1111/j.1471-4159.1993.tb09807.x. PMID: 7901331.

  118. Romero J, Berrendero F, Pérez-Rosado A, Manzanares J, Rojo A, Fernández-Ruiz JJ, de Yebenes JG, Ramos JA (2000): Unilateral 6-hydroxydopamine lesions of nigrostriatal dopaminergic neurons increased CB1 receptor mRNA levels in the caudate-putamen. Life Sci. 2000;66(6):485-94. doi: 10.1016/s0024-3205(99)00618-9. PMID: 10794065.

  119. Rohner H, Gaspar N, Philipsen A, Schulze M (2023): Prevalence of Attention Deficit Hyperactivity Disorder (ADHD) among Substance Use Disorder (SUD) Populations: Meta-Analysis. Int J Environ Res Public Health. 2023 Jan 10;20(2):1275. doi: 10.3390/ijerph20021275. PMID: 36674031; PMCID: PMC9859173. METASTUDIE

  120. Victor R, Gondwal R, Avinash P, Singhania R (2023): Decoding the link between substance dependence and attention deficit hyperactivity disorder in adults: A cross-sectional study from North India. Ind Psychiatry J. 2023 Jul-Dec;32(2):397-401. doi: 10.4103/ipj.ipj_47_23. PMID: 38161447; PMCID: PMC10756592.

  121. Beslot A, Grall-Bronnec M, Balem M, Schreck B, Laforgue EJ, Victorri-Vigneau C, Guillou-Landreat M, Leboucher J; OPAL-Group; Challet-Bouju G, Cabelguen C (2024): ADHD: prevalence and effect on opioid use disorder treatment outcome in a French sample of patients receiving medication for opioid use disorder-the influence of impulsivity as a mediating factor. Harm Reduct J. 2024 Sep 9;21(1):165. doi: 10.1186/s12954-024-01079-7. PMID: 39252018; PMCID: PMC11382469.

  122. Edel, Vollmoeller: Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Erwachsenen, 2006, Seite 107 f

  123. Manni, Cipollone, Pallucchini, Maremmani, Perugi, Maremmani (2019): Remarkable Reduction of Cocaine Use in Dual Disorder (Adult Attention Deficit Hyperactive Disorder/Cocaine Use Disorder) Patients Treated with Medications for ADHD. Int J Environ Res Public Health. 2019 Oct 15;16(20). pii: E3911. doi: 10.3390/ijerph16203911.

  124. Heradstveit, Skogen, Hetland, Stewart, Hysing (2019): Psychiatric Diagnoses Differ Considerably in Their Associations With Alcohol/Drug-Related Problems Among Adolescents. A Norwegian Population-Based Survey Linked With National Patient Registry Data. Front Psychol. 2019 May 8;10:1003. doi: 10.3389/fpsyg.2019.01003. eCollection 2019. n = 9.408

  125. August, Winters, Realmuto, Fahnhorst, Botzet, Lee (2006): Prospective study of adolescent drug use among community samples of ADHD and non-ADHD participants. J Am Acad Child Adolesc Psychiatry. 2006 Jul;45(7):824-32. doi: 10.1097/01.chi.0000219831.16226.f8. PMID: 16832319. n = 199

  126. Pomerleau, Downey, Stelson, Pomerleau (1995): Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder, Journal of Substance Abuse, Volume 7, Issue 3, 1995, Pages 373-378, ISSN 0899-3289, https://doi.org/10.1016/0899-3289(95)90030-6.

  127. Lambert, Hartsough, (1998): Prospective Study of Tobacco Smoking and Substance Dependencies Among Samples of ADHD and Non-ADHD Participants. Journal of Learning Disabilities, 31(6), 533–544. https://doi.org/10.1177/002221949803100603

  128. Müller, Candrian, Kropotov (2011): ADHS – Neurodiagnostik in der Praxis, S. 88

  129. http://de.statista.com/statistik/daten/studie/261015/umfrage/praevalenz-des-rauchens-in-deutschland-nach-geschlecht/

  130. Kollins, McClernon, Fuemmeler (2005): Association between smoking and attention-deficit/hyperactivity disorder symptoms in a population-based sample of young adults. Arch Gen Psychiatry. 2005 Oct;62(10):1142-7.

  131. Edel, Vollmoeller: Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Erwachsenen, 2006, Seite 106

  132. Steinhausen, Rothenberger, Döpfner (2010): Handbuch ADHS, Seite 78

  133. Roman ML, Vansteene C, Poupon D, Gorwood P (2025): Detecting the comorbidity of attention deficit hyperactivity disorder (ADHD) in a population of outpatients with alcohol use disorder (AUD): The role of personality traits, age at first alcohol use and level of craving. Alcohol. 2025 Feb;122:63-70. doi: 10.1016/j.alcohol.2024.11.001. PMID: 39505078.

  134. Krause, Biermann, Krause (2002): Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Alkoholikern. Nervenheilkunde 21 (2002): 156-159., zitiert nach Edel, Vollmoeller: Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Erwachsenen, 2006, Seite 106

  135. Lohit, Babu, Sharma, Rao, Sachin, Matkar (2019): Prevalence of Adult ADHD Co-morbidity in Alcohol Use Disorders in a General Hospital Setup. Indian J Psychol Med. 2019 Nov 11;41(6):523-528. doi: 10.4103/IJPSYM.IJPSYM_464_18. eCollection 2019 Nov-Dec.

  136. August, Winters, Realmuto, Fahnhorst, Botzet, Lee (2006): Prospective study of adolescent drug use among community samples of ADHD and non-ADHD participants. J Am Acad Child Adolesc Psychiatry. 2006 Jul;45(7):824-32. doi: 10.1097/01.chi.0000219831.16226.f8. PMID: 16832319.

  137. Philipsen, Heßlinger, Tebartz van Elst: AufmerksamkeitsdefizitHyperaktivitätsstörung im Erwachsenenalter – Diagnostik, Ätiologie und Therapie (ÜBERSICHTSARBEIT), Deutsches Ärzteblatt, Jg. 105, Heft 17, 25. April 2008, Seite 311 – 317, 313 , Seite 313 unter Verweis auf Rösler, Heßlinger, Philipsen (2007): ADHS im Erwachsenenalter. In: Voderholzer, Hohagen (Hrsg.): Therapie psychischer Erkrankungen – State of the Art. 2. Auflage. München: Urban & Fischer, 2007

  138. Edel, Vollmoeller: Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Erwachsenen, 2006, Seite 106 mwNw

  139. Biederman, Wilens, Mick, Milberger, Spencer, Faraone (1995): Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995 Nov;152(11):1652-8.

  140. Weiss et al. 1985, Gittelman et al. 1985, zitiert nach Oehler (2009), Vortrag beim 4. ADHS-Gipfel in Hamburg, 06.-08.02.2009

  141. Martínez-Luna, Daigre, Palma-Álvarez, Perea-Ortueta, Grau-López, Roncero, Castell-Panisello, Ramos-Quiroga (2019): Psychiatric Comorbidity and Addiction Severity Differences in Patients With ADHD Seeking Treatment for Cannabis or Cocaine Use Disorders. J Atten Disord. 2019 Sep 24:1087054719875787. doi: 10.1177/1087054719875787.

  142. Philipsen, Heßlinger, Tebartz van Elst: Aufmerksamkeitsdefizit-Hyperaktivitätsstörung im Erwachsenenalter – Diagnostik, Ätiologie und Therapie (ÜBERSICHTSARBEIT), Deutsches Ärzteblatt, Jg. 105, Heft 17, 25. April 2008, Seite 311 – 317, 313 Seite 313

  143. Lugoboni, Zamboni, Mantovani, Cibin, Tamburin (2020): Gruppo InterSERT di Collaborazione Scientifica. Association between Adult Attention Deficit/Hyperactivity Disorder and Intravenous Misuse of Opioid and Benzodiazepine in Patients under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study. Eur Addict Res. 2020 Jan 29;1-11. doi: 10.1159/000505207. PMID: 31995807. n = 1.649

  144. Riedinger (2011): ADHS und Sucht im Erwachsenenalter

  145. Levin, Evans, Kleber (1998): Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. Drug Alcohol Depend. 1998 Sep 1;52(1):15-25.

  146. Jacob, Haro, Koyanagi (2018): Relationship between attention-deficit hyperactivity disorder symptoms and problem gambling: A mediation analysis of influential factors among 7,403 individuals from the UK. J Behav Addict. 2018 Sep 21:1-11. doi: 10.1556/2006.7.2018.72. n = 7403

  147. So R, Sato Y, Hashimoto N, Furukawa TA (2023): Prevalence of suspected autism spectrum disorder and attention-deficit hyperactivity disorder in a Japanese clinical sample with gambling disorder: A cross-sectional study. PCN Rep. 2023 Aug 13;2(3):e131. doi: 10.1002/pcn5.131. PMID: 38867830; PMCID: PMC11114339.

  148. García-Marín, Campos, Cuéllar-Partida, Medland, Kollins, Rentería (2021): Large-scale genetic investigation reveals genetic liability to multiple complex traits influencing a higher risk of ADHD. Sci Rep. 2021 Nov 19;11(1):22628. doi: 10.1038/s41598-021-01517-7. PMID: 34799595.

  149. Prof. Dr. Tobias Renner, Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung Störungen des Sozialverhaltens; nicht mehr online

  150. Kessler, Adler, Barkley, Biederman, Conners, Demler, Faraone, Greenhill, Howes, Secnik, Spencer, Ustun, Walters, Zaslavsky (2006): The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. Am J Psychiatry. 2006 Apr;163(4):716-23. doi: 10.1176/ajp.2006.163.4.716. PMID: 16585449; PMCID: PMC2859678.

  151. Prävalenzraten des Konsums illegaler Drogen unter deutschen Erwachsenen - ausgewählten Substanzen im Jahr 2019, Statista

  152. Nikotinabhängigkeit, GenderMedWiki Uni Münster

  153. Alkoholabhängigkeit, GenderMedWiki Uni Münster

  154. Luderer, Sick, Kaplan-Wickel, Reinhard, Richter, Kiefer, Weber (2020): Prevalence Estimates of ADHD in a Sample of Inpatients With Alcohol Dependence. J Atten Disord. 2020 Dec;24(14):2072-2083. doi: 10.1177/1087054717750272. PMID: 29308693.

  155. Glass, Flory, Martin, Hankin, (2011). ADHD and comorbid conduct problems among adolescents: Associations with self-esteem and substance use. ADHD Attention Deficit and Hyperactivity Disorders, 3, 29–39, zitiert nach Sören Schmidt und Franz Petermann, ADHS über die Lebensspanne – Symptome und neue diagnostische Ansätze, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 59 (3), 2011, 227–238, Seite 229

  156. Brook, Duan, Zhang, Cohen, Brook, (2008). The association between attention deficit hyperactivity disorder in adolescence and smoking in Adulthood. American Journal on Addictions, 17, 54 – 59., zitiert nach Sören Schmidt und Franz Petermann, ADHS über die Lebensspanne – Symptome und neue diagnostische Ansätze, Zeitschrift für Psychiatrie, Psychologie und Psychotherapie, 59 (3), 2011, 227–238, Seite 229

  157. Slobodin, Blankers, Kapitány-Fövény, Kaye, Berger, Johnson, Demetrovics, van den Brink, van de Glind (2020): Differential Diagnosis in Patients with Substance Use Disorder and/or Attention-Deficit/Hyperactivity Disorder Using Continuous Performance Test. Eur Addict Res. 2020;26(3):151-162. doi: 10.1159/000506334. PMID: 32074617.

  158. Prof. Dr. Tobias Renner, Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung Störungen des Sozialverhaltens

  159. Kraus, Seitz, Rauschert (2020): Epidemiologischer Suchtsurvey Berlin 2018

  160. Deutsche Hauptstelle für Suchtfragen (2019): Jahrbuch Sucht 2019, S. 106

  161. Treur, Demontis, Smith, Sallis, Richardson, Wiers, Børglum, Verweij, Munafò (2019): Investigating causality between liability to ADHD and substance use, and liability to substance use and ADHD risk, using Mendelian randomization. Addict Biol. 2019 Nov 16:e12849. doi: 10.1111/adb.12849.

  162. Wimberley, Agerbo, Horsdal, Ottosen, Brikell, Als, Demontis, Børglum, Nordentoft, Mors, Werge, Hougaard, Bybjerg-Grauholm, Hansen, Mortensen, Thapar, Riglin, Langley, Dalsgaard (2019): Genetic liability to ADHD and substance use disorders in individuals with ADHD. Addiction. 2019 Dec 5. doi: 10.1111/add.14910.

  163. Brunklaus (2006): Vergleich von Symptomen des Hyperkinetischen Syndroms bei politoxikomanen Patienten in Suchtbehandlung und gesunden Kontrollprobanden, Dissertation, 6.2.4

  164. Brunklaus (2006): Vergleich von Symptomen des Hyperkinetischen Syndroms bei politoxikomanen Patienten in Suchtbehandlung und gesunden Kontrollprobanden, Dissertation, 6.2.5

  165. Brunklaus (2006): Vergleich von Symptomen des Hyperkinetischen Syndroms bei politoxikomanen Patienten in Suchtbehandlung und gesunden Kontrollprobanden, Dissertation, 6.2.6

  166. Brunklaus (2006): Vergleich von Symptomen des Hyperkinetischen Syndroms bei politoxikomanen Patienten in Suchtbehandlung und gesunden Kontrollprobanden, Dissertation, 6.2.8

  167. Vaziri-Harami R, Khademi M, Zolfaghari A, Vaziri-Harami S (2024): Patterns of substance use and initiation timing in adults with substance abuse: a comparison between those with and without attention deficit hyperactivity disorder. Ann Med Surg (Lond). 2024 Jun 13;86(8):4397-4401. doi: 10.1097/MS9.0000000000002272. PMID: 39118714; PMCID: PMC11305728.

  168. Hässler, Irmisch: Biochemische Störungen bei Kindern mit AD(H)S, Seite 88, in Steinhausen (Hrsg.) (2000): Hyperkinetische Störungen bei Kindern, Jugendlichen und Erwachsenen, 2. Aufl., Kohlhammer

  169. Migueis DP, Lopes MC, Casella E, Soares PV, Soster L, Spruyt K (2023): Attention deficit hyperactivity disorder and restless leg syndrome across the lifespan: A systematic review and meta-analysis. Sleep Med Rev. 2023 Feb 27;69:101770. doi: 10.1016/j.smrv.2023.101770. PMID: 36924608. METASTUDIE

  170. Oner, Dirik, Taner, Caykoylu, Anlar (2007): Association between low serum ferritin and restless legs syndrome in patients with attention deficit hyperactivity disorder. Tohoku J Exp Med. 2007 Nov;213(3):269-76. doi: 10.1620/tjem.213.269. PMID: 17984624. n = 87

  171. Cortese, Konofal, Lecendreux, Arnulf, Mouren, Darra, Dalla Bernardina (2005): Restless legs syndrome and attention-deficit/hyperactivity disorder: a review of the literature. Sleep. 2005 Aug 1;28(8):1007-13. doi: 10.1093/sleep/28.8.1007. PMID: 16218085. REVIEW

  172. Zak, Fisher, Couvadelli, Moss, Walters (2009): Preliminary study of the prevalence of restless legs syndrome in adults with attention deficit hyperactivity disorder. Percept Mot Skills. 2009 Jun;108(3):759-63. doi: 10.2466/PMS.108.3.759-763. PMID: 19725311. n = 30

  173. Huang, Chen, Li, Wu, Chao, Guilleminault (2004): Sleep disorders in Taiwanese children with attention deficit/hyperactivity disorder. J Sleep Res. 2004 Sep;13(3):269-77. doi: 10.1111/j.1365-2869.2004.00408.x. PMID: 15339263. n = 88

  174. Picchietti, Underwood, Farris, Walters, Shah, Dahl, Trubnick, Bertocci, Wagner, Hening (1999): Further studies on periodic limb movement disorder and restless legs syndrome in children with attention-deficit hyperactivity disorder. Mov Disord. 1999 Nov;14(6):1000-7. doi: 10.1002/1531-8257(199911)14:6<1000::aid-mds1014>3.0.co;2-p. PMID: 10584676.

  175. Fulda S, Miano S. Time to rest a hypothesis? Accumulating evidence that periodic leg movements during sleep are not increased in children with attention deficit hyperactivity disorder (ADHD): results of a case-control study and a meta-analysis. Sleep. 2023 Mar 3:zsad046. doi: 10.1093/sleep/zsad046. Epub ahead of print. PMID: 36869787. METASTUDIE

  176. Didriksen, Thørner, Erikstrup, Pedersen, Paarup, Petersen, Hansen, Banasik, Nielsen, Hjalgrim, Jennum, Sørensen, Burgdorf, Ullum (2019): Self-reported restless legs syndrome and involuntary leg movements during sleep are associated with symptoms of attention deficit hyperactivity disorder. Sleep Med. 2019 Feb 11;57:115-121. doi: 10.1016/j.sleep.2019.01.039. n = 25.336

  177. Picchietti, Allen, Walters, Davidson, Myers, Ferini-Strambi (2007): Restless legs syndrome: prevalence and impact in children and adolescents–the Peds REST study. Pediatrics. 2007 Aug;120(2):253-66. doi: 10.1542/peds.2006-2767. PMID: 17671050.

  178. Tilma, Thomsen, Ostergaard (2014): [A possible coexistence between restless legs syndrom and attention deficit hyperactivity disorder]. Ugeskr Laeger. 2014 Feb 17;176(4):V11120672. Danish. PMID: 25095868. REVIEW

  179. Konofal, Cortese, Marchand, Mouren, Arnulf, Lecendreux (2007): Impact of restless legs syndrome and iron deficiency on attention-deficit/hyperactivity disorder in children. Sleep Med. 2007 Nov;8(7-8):711-5. doi: 10.1016/j.sleep.2007.04.022. PMID: 17644481.

  180. Konofal, Lecendreux, Arnulf, Mouren (2004): Iron deficiency in children with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2004 Dec;158(12):1113-5. doi: 10.1001/archpedi.158.12.1113. PMID: 15583094.

  181. Lahat, Heyman, Livne, Goldman, Berkovitch, Zachor (2011): Iron deficiency in children with attention deficit hyperactivity disorder. Isr Med Assoc J. 2011 Sep;13(9):530-3. PMID: 21991711.

  182. Millichap, Yee, Davidson (2006): Serum ferritin in children with attention-deficit hyperactivity disorder. Pediatr Neurol. 2006 Mar;34(3):200-3. doi: 10.1016/j.pediatrneurol.2005.09.001. PMID: 16504789.

  183. Cortese, Angriman (2014): Attention-deficit/hyperactivity disorder, iron deficiency, and obesity: is there a link? Postgrad Med. 2014 Jul;126(4):155-70. doi: 10.3810/pgm.2014.07.2793. PMID: 25141253. REVIEW

  184. Trenkwalder, Paulus (2010): Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol. 2010 Jun;6(6):337-46. doi: 10.1038/nrneurol.2010.55. PMID: 20531433. REVIEW

  185. Picchietti MA, Picchietti DL. Advances in pediatric restless legs syndrome: Iron, genetics, diagnosis and treatment. Sleep Med. 2010 Aug;11(7):643-51. doi: 10.1016/j.sleep.2009.11.014. PMID: 20620105. REVIEW

  186. Simakajornboon, Kheirandish-Gozal, Gozal (2009): Diagnosis and management of restless legs syndrome in children. Sleep Med Rev. 2009 Apr;13(2):149-56. doi: 10.1016/j.smrv.2008.12.002. PMID: 19186083; PMCID: PMC2911577. REVIEW

  187. Connor, Boyer, Menzies, Dellinger, Allen, Ondo, Earley (2003): Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology. 2003 Aug 12;61(3):304-9. doi: 10.1212/01.wnl.0000078887.16593.12. PMID: 12913188.

  188. Allen, Earley (2007): The role of iron in restless legs syndrome. Mov Disord. 2007;22 Suppl 18:S440-8. doi: 10.1002/mds.21607. Erratum in: Mov Disord. 2008 Jun;23(8):1200-2. PMID: 17566122. REVIEW

  189. Konofal, Lecendreux, Deron, Marchand, Cortese, Zaïm, Mouren, Arnulf (2008): Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatr Neurol. 2008 Jan;38(1):20-6. doi: 10.1016/j.pediatrneurol.2007.08.014. PMID: 18054688. n = 23

  190. Ferré, Guitart, Quiroz, Rea, García-Malo, Garcia-Borreguero, Allen, Earley (2021): Akathisia and Restless Legs Syndrome: Solving the Dopaminergic Paradox. Sleep Med Clin. 2021 Jun;16(2):249-267. doi: 10.1016/j.jsmc.2021.02.012. PMID: 33985651.

  191. P LMB, E SSA, Castro-Villacañas, Garcia-Borreguero (2021): Restless Legs Syndrome: Challenges to Treatment. Sleep Med Clin. 2021 Jun;16(2):269-277. doi: 10.1016/j.jsmc.2021.02.003. PMID: 33985652.

  192. England, Picchietti, Couvadelli, Fisher, Siddiqui, Wagner, Hening, Lewin, Winnie, Cohen, Walters (2011): L-Dopa improves Restless Legs Syndrome and periodic limb movements in sleep but not Attention-Deficit-Hyperactivity Disorder in a double-blind trial in children. Sleep Med. 2011 May;12(5):471-7. doi: 10.1016/j.sleep.2011.01.008. PMID: 21463967; PMCID: PMC3094572.

  193. Konofal, Arnulf, Lecendreux, Mouren (2005): Ropinirole in a child with attention-deficit hyperactivity disorder and restless legs syndrome. Pediatr Neurol. 2005 May;32(5):350-1. doi: 10.1016/j.pediatrneurol.2004.11.007. PMID: 15866437.

  194. Büber, Başay, Şenol (2020): The prevalence and comorbidity rates of specific learning disorder among primary school children in Turkey. Nord J Psychiatry. 2020 Aug;74(6):453-460. doi: 10.1080/08039488.2020.1740782. PMID: 32186228. n = 1.041

  195. Rothenberger, Lauth, Ramacher-Faasen, Braun, Bock, von Aster, von Aster, von Aster in Lernen und Lernstörungen (2014), 3, pp. 185-202. DOI: 10.1024/2235-0977/a000071:

  196. Kommentare zu Romanos & Jans (2014). ADHS-HI – an der Nahtstelle von Medizin und Pädagogik. Lernen und Lernstörungen, 3, 117 – 132; DOI: http://dx.doi.org/10.1024/2235-0977/a000071

  197. Ciulkinyte A, Mountford HS, Fontanillas P; 23andMe Research Team; Bates TC, Martin NG, Fisher SE, Luciano M (2024): Genetic neurodevelopmental clustering and dyslexia. Mol Psychiatry. 2024 Jul 15. doi: 10.1038/s41380-024-02649-8. PMID: 39009701.

  198. van Bergen E, de Zeeuw EL, Hart SA, Boomsma DI, de Geus EJC, Kan KJ (2025): *Co-Occurrence and Causality Among ADHD, Dyslexia, and Dyscalculia. Psychol Sci. 2025 Mar;36(3):204-217. doi: 10.1177/09567976241293999. PMID: 40098496.

  199. McGrath, Stoodley (2019): Are there shared neural correlates between dyslexia and ADHD? A meta-analysis of voxel-based morphometry studies. J Neurodev Disord. 2019 Nov 21;11(1):31. doi: 10.1186/s11689-019-9287-8.

  200. Sarisuta P, Chunsuwan I, Hansakunachai T, Sritipsukho P. Attention-deficit/hyperactive-impulsive disorder symptoms among grade 1 students with reading disorder in Thailand. Clin Exp Pediatr. 2023 Nov;66(11):485-492. doi: 10.3345/cep.2023.00773. PMID: 37873565; PMCID: PMC10626022. n = 703

  201. Horowitz-Kraus, Hershey, Kay, DiFrancesco (2019): Differential effect of reading training on functional connectivity in children with reading difficulties with and without ADHD comorbidity. J Neurolinguistics. 2019 Feb;49:93-108. doi: 10.1016/j.jneuroling.2018.09.002.

  202. Schuhmacher (2016): Fehler muss man sehen! Visuelle Funktions- und Informationsverarbeitungsstörungen bei Schulkindern. Vortrag, Youtube

  203. Haider S, Mondal T, Loffredo CA, Korba B, Nawaz I, Azam M, Sur T, Ghosh S (2025): Epidemiological Investigation on the Clinical Status of the Developmental Dyslexia and ADHD Comorbidity among School-Age Children in Pakistan. Open J Epidemiol. 2025 Aug;15(3):528-541. doi: 10.4236/ojepi.2025.153033. PMID: 40855875; PMCID: PMC12373264.

  204. Edel, Vollmoeller: Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung bei Erwachsenen, 2006, Seite 40

  205. Daucourt, Erbeli, Little, Haughbrook, Hart (2020): A Meta-Analytical Review of the Genetic and Environmental Correlations between Reading and Attention-Deficit Hyperactivity Disorder Symptoms and Reading and Math. Sci Stud Read. 2020;24(1):23-56. doi: 10.1080/10888438.2019.1631827. PMID: 32189961; PMCID: PMC7079676. METASTUDIE

  206. Kanevski M, Booth JN, Stewart TM, Rhodes SM (2024): Cognitive heterogeneity in Attention Deficit Hyperactivity Disorder: Implications for maths. Br J Dev Psychol. 2024 Nov;42(4):596-621. doi: 10.1111/bjdp.12517. PMID: 39166844.

  207. Gaye F, Harmon SL, Cole AM, Marsh CL, Liu Q, Mcintosh A, Kofler MJ (2025): Examining the roles of working memory and trait anxiety on math achievement in children with ADHD. Neuropsychology. 2025 Mar;39(3):259-274. doi: 10.1037/neu0000994. PMID: 40063373; PMCID: PMC11926614.

  208. Lauth: ADHS bei Erwachsenen: Diagnostik und Behandlung von Aufmerksamkeits-/ Hyperaktivitätsstörungen, Seite 97

  209. Varheenmaa M, Lehto SM, Rizzo P, Steinhausen HC, Drechsler R, Brem AK (2024): Facial emotion recognition in children with attention deficit hyperactivity disorder. Nord J Psychiatry. 2024 Oct;78(7):634-643. doi: 10.1080/08039488.2024.2403589. PMID: 39294899; PMCID: PMC11458127.

  210. Mansour S, Mwafi N, Al-Tawarah N, Masoud B, Ab{u-Tapanjeh H, Alkhawaldeh I, Qawaqzeh M, Amro R, Mazahreh S (2023): PREVALENCE OF LEFT/RIGHT CONFUSION AMONG MEDICAL STUDENTS IN MUTAH UNIVERSITY- JORDAN. Georgian Med News. 2023 Nov;(344):85-89. PMID: 38236104.

  211. Meier, Pavlova, Dalsgaard, Nordentoft, Mors, Mortensen, Uher (2018): Attention-deficit hyperactivity disorder and anxiety disorders as precursors of bipolar disorder onset in adulthood. Br J Psychiatry. 2018 Sep;213(3):555-560. doi: 10.1192/bjp.2018.111.

  212. Fahrendorff AM, Pagsberg AK, Kessing LV, Maigaard K (2023): Psychiatric comorbidity in patients with pediatric bipolar disorder - A systematic review. Acta Psychiatr Scand. 2023 Mar 20. doi: 10.1111/acps.13548. PMID: 36941106.

  213. Mishra VC, Solanki G, Singh D, Goyal MK (2023): Prevalence and clinical correlates of co-morbid attention deficit hyperactivity disorder in euthymic adults with bipolar disorder: A cross-sectional study. Indian J Psychiatry. 2023 Nov;65(11):1129-1136. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_647_23. PMID: 38249150; PMCID: PMC10795658. n = 110

  214. Pinna, Visioli, Rago, Manchia, Tondo, Baldessarini (2018): Attention deficit-hyperactivity disorder in adult bipolar disorder patients. J Affect Disord. 2018 Sep 17;243:391-396. doi: 10.1016/j.jad.2018.09.038.

  215. Hossain, Mainali, Bhimanadham, Imran, Ahmad, Patel (2019): Medical and Psychiatric Comorbidities in Bipolar Disorder: Insights from National Inpatient Population-based Study. Cureus. 2019 Sep 12;11(9):e5636. doi: 10.7759/cureus.5636.

  216. Grigoroiu-Serbanescu, Giaroli, Thygesen, Shenyan, Bigdeli, Bass, Diaconu, Neagu, Forstner, Degenhardt, Herms, Nöthen, McQuillin (2019): Predictive power of the ADHD GWAS 2019 polygenic risk scores in independent samples of bipolar patients with childhood ADHD. J Affect Disord. 2019 Nov 23. pii: S0165-0327(19)32310-9. doi: 10.1016/j.jad.2019.11.109.

  217. O’Connell, Shadrin, Bahrami, Smeland, Bettella, Frei, Krull, Askeland, Walters, Davíðsdóttir, Haraldsdóttir, Guðmundsson, Stefánsson, Fan, Steen, Reichborn-Kjennerud, Dale, Stefánsson, Djurovic, Andreassen (2019): Identification of genetic overlap and novel risk loci for attention-deficit/hyperactivity disorder and bipolar disorder. Mol Psychiatry. 2019 Dec 2. doi: 10.1038/s41380-019-0613-z. n = 105.000

  218. Adamis D, Kasianenko D, Usman M, Saleem F, Wrigley M, Gavin B, McNicholas F (2023): Prevalence of Personality Disorders in Adults With Attention Deficit Hyperactivity Disorder (ADHD). J Atten Disord. 2023 Mar 16:10870547231161531. doi: 10.1177/10870547231161531. PMID: 36927130. n = 147

  219. Mannuzza, Klein, Bessler, Malloy, LaPadula (1993): Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Arch Gen Psychiatry. 1993 Jul;50(7):565-76. doi: 10.1001/archpsyc.1993.01820190067007. PMID: 8317950. n = 103

  220. Nach ADHS-Netzwerkstudie “Persönlichkeitsstörungen”, n = 156, zitiert nach NICOLAY (2009); IPSM-adhs Grundlagen, Teil 3

  221. Buitelaar, Posthumus, Bijlenga, Buitelaar (2019): The Impact of ADHD Treatment on Intimate Partner Violence in a Forensic Psychiatry Setting. J Atten Disord. 2019 Oct 16:1087054719879502. doi: 10.1177/1087054719879502.

  222. Matthies S, van Elst LT, Feige B, Fischer D, Scheel C, Krogmann E, Perlov E, Ebert D, Philipsen A (2011): Severity of childhood attention-deficit hyperactivity disorder–a risk factor for personality disorders in adult life? J Pers Disord. 2011 Feb;25(1):101-14. doi: 10.1521/pedi.2011.25.1.101. PMID: 21309626.

  223. Kuja-Halkola R, Lind Juto K, Skoglund C, Rück C, Mataix-Cols D, Pérez-Vigil A, Larsson J, Hellner C, Långström N, Petrovic P, Lichtenstein P, Larsson H (2021): Do borderline personality disorder and attention-deficit/hyperactivity disorder co-aggregate in families? A population-based study of 2 million Swedes. Mol Psychiatry. 2021 Jan;26(1):341-349. doi: 10.1038/s41380-018-0248-5. PMID: 30323291; PMCID: PMC7815504.

  224. Jacob CP, Romanos J, Dempfle A, Heine M, Windemuth-Kieselbach C, Kruse A, Reif A, Walitza S, Romanos M, Strobel A, Brocke B, Schäfer H, Schmidtke A, Böning J, Lesch KP (2007): Co-morbidity of adult attention-deficit/hyperactivity disorder with focus on personality traits and related disorders in a tertiary referral center. Eur Arch Psychiatry Clin Neurosci. 2007 Sep;257(6):309-17. doi: 10.1007/s00406-007-0722-6. PMID: 17401730.

  225. Ditrich I, Philipsen A, Matthies S (2021): Borderline personality disorder (BPD) and attention deficit hyperactivity disorder (ADHD) revisited - a review-update on common grounds and subtle distinctions. Borderline Personal Disord Emot Dysregul. 2021 Jul 6;8(1):22. doi: 10.1186/s40479-021-00162-w. PMID: 34229766; PMCID: PMC8261991. REVIEW

  226. Weibel S, Nicastro R, Prada P, Cole P, Rüfenacht E, Pham E, Dayer A, Perroud N (2018): Screening for attention-deficit/hyperactivity disorder in borderline personality disorder. J Affect Disord. 2018 Jan 15;226:85-91. doi: 10.1016/j.jad.2017.09.027. PMID: 28964997.

  227. Philipsen A, Limberger MF, Lieb K, Feige B, Kleindienst N, Ebner-Priemer U, Barth J, Schmahl C, Bohus M (2008): Attention-deficit hyperactivity disorder as a potentially aggravating factor in borderline personality disorder. Br J Psychiatry. 2008 Feb;192(2):118-23. doi: 10.1192/bjp.bp.107.035782. PMID: 18245028.

  228. Fossati A, Novella L, Donati D, Donini M, Maffei C (2002): History of childhood attention deficit/hyperactivity disorder symptoms and borderline personality disorder: a controlled study. Compr Psychiatry. 2002 Sep-Oct;43(5):369-77. doi: 10.1053/comp.2002.34634. PMID: 12216012.

  229. Broughton T, Lambert E, Wertz J, Agnew-Blais J (2025): Increased risk of provisional premenstrual dysphoric disorder (PMDD) among females with attention-deficit hyperactivity disorder (ADHD): cross-sectional survey study. Br J Psychiatry. 2025 Jun;226(6):410-417. doi: 10.1192/bjp.2025.104. PMID: 40528384; PMCID: PMC7617793. n = 715

  230. ADHS Deutschland Selbsthilfe Aachen. Abgerufen am 26.01.2024

  231. Rapanelli M, Frick L, Pogorelov V, Ohtsu H, Bito H, Pittenger C (2017): Histamine H3R receptor activation in the dorsal striatum triggers stereotypies in a mouse model of tic disorders. Transl Psychiatry. 2017 Jan 24;7(1):e1013. doi: 10.1038/tp.2016.290. PMID: 28117842; PMCID: PMC5545743.

  232. Magdi HM, Abousoliman AD, Lbrahim AM, Elsehrawy MG, El-Gazar HE, Zoromba MA (2025): Attention-deficit/hyperactivity disorder and post-traumatic stress disorder adult comorbidity: a systematic review. Syst Rev. 2025 Feb 14;14(1):41. doi: 10.1186/s13643-025-02774-7. PMID: 39953536; PMCID: PMC11829347. REVIEW

  233. Wilson J, Fida D, Maurer R, Wiley A, Rajasekera T, Spagnolo P (2025): Sex Differences in the Comorbidity between Attention Deficit-Hyperactivity Disorder and Posttraumatic Stress Disorder: A Systematic Literature Review and Meta-Analysis. medRxiv [Preprint]. 2025 Jan 10:2025.01.10.25320323. doi: 10.1101/2025.01.10.25320323. Update in: Gen Hosp Psychiatry. 2025 Apr 12;95:32-39. doi: 10.1016/j.genhosppsych.2025.04.003. PMID: 39830260; PMCID: PMC11741499. METASTUDY

  234. Knight AR, Kim S, Currao A, Lebas A, Nowak MK, Milberg WP, Fortier CB (2025): Assessing Attention-Deficit/Hyperactivity Disorder in Post-9/11 Veterans: Prevalence, Measurement Correspondence, and Comorbidity With Posttraumatic Stress Disorder. Mil Med. 2025 Apr 23;190(5-6):e1106-e1113. doi: 10.1093/milmed/usae539. PMID: 39607449; PMCID: PMC12016034.

  235. Hängen Übergewicht und ADHS bei Kindern zusammen?

  236. Reinblatt, Mahone, Tanofsky-Kraff, Lee-Winn, Yenokyan, Leoutsakos, Moran, Guarda, Riddle (2015): Pediatric loss of control eating syndrome: Association with attention-deficit/hyperactivity disorder and impulsivity. Int J Eat Disord. 2015 Sep;48(6):580-8. doi: 10.1002/eat.22404.

  237. Mohammadi, Mostafavi, Hooshyari, Khaleghi, Ahmadi, Molavi, Armani Kian, Safavi, Delpisheh, Talepasand, Hojjat, Pourdehghan, Ostovar, Hosseini, Mohammadzadeh, Salmanian, Alavi, Ahmadi, Zarafshan (2019): Prevalence, correlates and comorbidities of feeding and eating disorders in a nationally representative sample of Iranian children and adolescents. Int J Eat Disord. 2019 Nov 19. doi: 10.1002/eat.23197. n = 27.111

  238. Schiros A, Antshel KM (2022): The relationship between anorexia nervosa and bulimia nervosa, attention deficit/hyperactivity disorder, and suicidality in college students. Eur Eat Disord Rev. 2022 Dec 5. doi: 10.1002/erv.2962. PMID: 36468533. n = 342.432

  239. Namimi-Halevi C, Dor C, Stark AH, Dichtiar R, Bromberg M, Sinai T (2023): Attention-deficit hyperactivity disorder is associated with disordered eating in adolescents. Pediatr Res. 2023 Dec 4. doi: 10.1038/s41390-023-02925-3. PMID: 38049648.

  240. Wang S, Yao B, Zhang H, Xia L, Yu S, Peng X, Xiang D, Liu Z (2023): Comorbidity of epilepsy and attention-deficit/hyperactivity disorder: a systematic review and meta-analysis. J Neurol. 2023 Jun 16. doi: 10.1007/s00415-023-11794-z. PMID: 37326829.

  241. Fu J, Li Q, Zhang G, Yang Z, Qin J (2025): Neuropsychiatric disorders in Chinese pediatric tuberous sclerosis complex patients associated with drug-resistant epilepsy: A TAND checklist-based survey. Epilepsy Behav Rep. 2025 Apr 3;30:100765. doi: 10.1016/j.ebr.2025.100765. PMID: 40242083; PMCID: PMC12001132.

  242. Ashjazadeh, Sahraeian, Sabzgolin, Asadi-Pooya (2019): Attention-deficit hyperactivity disorder in adults with epilepsy. Epilepsy Behav. 2019 Nov 4;101(Pt A):106543. doi: 10.1016/j.yebeh.2019.106543. n = 200

  243. Ahlqvist VH, Dardani C, Madley-Dowd P, Forbes H, Rast J, Zhong C, Gardner RM, Dalman C, Lyall K, Newschaffer C, Tomson T, Lundberg M, Berglind D, Davies NM, Lee BK, Magnusson C, Rai D (2024): Psychiatric comorbidities in epilepsy: population co-occurrence, genetic correlations and causal effects. Gen Psychiatr. 2024 Jan 30;37(1):e101201. doi: 10.1136/gpsych-2023-101201. PMID: 39228867; PMCID: PMC11369844. n = 7.628.495

  244. Dunbar, Lee, Maheshwari (2019): High Yield of Screening for ADHD in the Epilepsy Monitoring Unit. J Atten Disord. 2019 Nov 9:1087054719886359. doi: 10.1177/1087054719886359.

  245. Uliel-Sibony S, Chernuha V, Latzer IT, Leitner Y (2023): Epilepsy and attention-deficit/hyperactivity disorder in children and adolescents: An overview of etiology, prevalence, and treatment. Front Hum Neurosci. 2023 Apr 11;17:1021605. doi: 10.3389/fnhum.2023.1021605. PMID: 37113319; PMCID: PMC10126237.

  246. Nourredine M, Gering A, Fourneret P, Rolland B, Falissard B, Cucherat M, Geoffray MM, Jurek L (2021): Association of Attention-Deficit/Hyperactivity Disorder in Childhood and Adolescence With the Risk of Subsequent Psychotic Disorder: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021 May 1;78(5):519-529. doi: 10.1001/jamapsychiatry.2020.4799. PMID: 33625499; PMCID: PMC7905700. METASTUDY

  247. Schulze JB, Simnacher F, Müller TJ, Kirchebner J, Quatela F, Mikutta C, Euler S, von Känel R, Günther MP (2025): ADHD and schizophrenia: Mere prodromal variant or homogeneous subgroup? Schizophr Res Cogn. 2025 Jun 18;42:100374. doi: 10.1016/j.scog.2025.100374. PMID: 40605957; PMCID: PMC12214124.

  248. Jeon SM, Lee DY, Cha S, Kwon JW (2023): Psychiatric Comorbidities and Schizophrenia in Youths With Attention-Deficit/Hyperactivity Disorder. JAMA Netw Open. 2023 Nov 1;6(11):e2345793. doi: 10.1001/jamanetworkopen.2023.45793. PMID: 38032637; PMCID: PMC10690465. n = 211.705

  249. Arican I, Bass N, Neelam K, Wolfe K, McQuillin A, Giaroli G (2019): Prevalence of attention deficit hyperactivity disorder symptoms in patients with schizophrenia. Acta Psychiatr Scand. 2019 Jan;139(1):89-96. doi: 10.1111/acps.12948. PMID: 30105761; PMCID: PMC6412852. METASTUDY

  250. Arican I, Bass N, Neelam K, Wolfe K, McQuillin A, Giaroli G (2019): Prevalence of attention deficit hyperactivity disorder symptoms in patients with schizophrenia. Acta Psychiatr Scand. 2019 Jan;139(1):89-96. doi: 10.1111/acps.12948. PMID: 30105761; PMCID: PMC6412852. n = 126

  251. Huang, Cheng, Tsai, Bai, Li, Lin, Su, Chen, Chen (2020): Familial coaggregation of major psychiatric disorders among first-degree relatives of patients with obsessive-compulsive disorder: a nationwide study. Psychol Med. 2020 Jan 7:1-8. doi: 10.1017/S0033291719003696. n = 89.500

  252. Sawitzky-Rose (2011): Assoziation von ADHS und Übergewicht bei Kindern und Jugendlichen in Deutschland: Ergebnisse der BELLA-Studie, Dissertation

  253. Barkley, Murphy (1998): ADHD: A Clinical Workbook; Milwaukee Young Adult Outcome Study, zitiert nach Oehler (2009), Vortrag beim 4. ADHS-Gipfel in Hamburg, 06.-08.02.2009

  254. Skoglund, Kopp Kallner, Skalkidou, Wikström, Lundin, Hesselman, Wikman, Sundström Poromaa (2019): Association of Attention-Deficit/Hyperactivity Disorder With Teenage Birth Among Women and Girls in Sweden. JAMA Netw Open. 2019 Oct 2;2(10):e1912463. doi: 10.1001/jamanetworkopen.2019.12463. n = 384.103

  255. Kartal E, Scott J, Morein-Zamir S (2025): Attitudes to possessions in emerging adults: Predictors of hoarding behaviours and beliefs. Br J Clin Psychol. 2025 Jul 1. doi: 10.1111/bjc.70003. PMID: 40590164.

  256. Kuwano, Nakao, Yonemoto, Yamada, Murayama, Okada, Honda, Ikari, Tomiyama, Hasuzawa, Kanba (2020): Clinical characteristics of hoarding disorder in Japanese patients. Heliyon. 2020 Mar 6;6(3):e03527. doi: 10.1016/j.heliyon.2020.e03527. PMID: 32181397; PMCID: PMC7063155. n = 71

  257. Grassi G, Scillitani E, Moradei C, Cecchelli C, van Ameringen M, Rodriguez CI (2025): Long-term changes of hoarding symptoms among adults with attention-deficit/hyperactivity disorder (ADHD) treated with methylphenidate. J Psychiatr Res. 2025 Oct;190:102-111. doi: 10.1016/j.jpsychires.2025.07.031. PMID: 40768777.

  258. Tsai, Chang, Chen, Jeng, Yang, Wu (2020): Associations Between Psychiatric Disorders and Enuresis in Taiwanese Children: A National Population-Based Study. Clin Epidemiol. 2020 Feb 18;12:163-171. doi: 10.2147/CLEP.S230537. PMID: 32110107; PMCID: PMC7035896.

  259. Septier, Stordeur, Zhang, Delorme, Cortese (2019): Association between suicidal spectrum behaviors and Attention-Deficit/Hyperactivity Disorder: A systematic review and meta-analysis. Neurosci Biobehav Rev. 2019 Aug;103:109-118. doi: 10.1016/j.neubiorev.2019.05.022.

  260. Levy, Kronenberg, Crosbie, Schachar (2020): Attention-deficit/hyperactivity disorder (ADHD) symptoms and suicidality in children: The mediating role of depression, irritability and anxiety symptoms. J Affect Disord. 2020 Mar 15;265:200-206. doi: 10.1016/j.jad.2020.01.022. PMID: 32090742. n = 1.517

  261. Yılmaz, Tamam (2018): Attention-deficit hyperactivity disorder and impulsivity in female patients with fibromyalgia. Neuropsychiatr Dis Treat. 2018 Jul 24;14:1883-1889. doi: 10.2147/NDT.S159312. eCollection 2018. n = 132

  262. Spaull RVV, Kurian MA (2017): SLC6A3-Related Dopamine Transporter Deficiency Syndrome. 2017 Jul 27 [updated 2023 Sep 28]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025. PMID: 28749637. REVIEW

  263. Ng J, Zhen J, Meyer E, Erreger K, Li Y, Kakar N, Ahmad J, Thiele H, Kubisch C, Rider NL, Morton DH, Strauss KA, Puffenberger EG, D’Agnano D, Anikster Y, Carducci C, Hyland K, Rotstein M, Leuzzi V, Borck G, Reith ME, Kurian MA (2014): Dopamine transporter deficiency syndrome: phenotypic spectrum from infancy to adulthood. Brain. 2014 Apr;137(Pt 4):1107-19. doi: 10.1093/brain/awu022. PMID: 24613933; PMCID: PMC3959557.

  264. Puffenberger EG, Jinks RN, Sougnez C, Cibulskis K, Willert RA, Achilly NP, Cassidy RP, Fiorentini CJ, Heiken KF, Lawrence JJ, Mahoney MH, Miller CJ, Nair DT, Politi KA, Worcester KN, Setton RA, Dipiazza R, Sherman EA, Eastman JT, Francklyn C, Robey-Bond S, Rider NL, Gabriel S, Morton DH, Strauss KA (2012): Genetic mapping and exome sequencing identify variants associated with five novel diseases. PLoS One. 2012;7(1):e28936. doi: 10.1371/journal.pone.0028936. PMID: 22279524; PMCID: PMC3260153.

  265. Walsh B, Tichenor SE, Gerwin KL (2025): The Significance of a Higher Prevalence of ADHD and ADHD Symptoms in Children Who Stutter. J Speech Lang Hear Res. 2025 Jun 5;68(6):2741-2758. doi: 10.1044/2025_JSLHR-24-00668. PMID: 40366906; PMCID: PMC12173216. n = 204

  266. Chen, Pan, Huang, Hsu, Bai, Su, Li, Tsai, Cheng, Chen (2019): Coaggregation of Major Psychiatric Disorders in First-Degree Relatives of Individuals With Attention-Deficit/Hyperactivity Disorder: A Nationwide Population-Based Study. J Clin Psychiatry. 2019 Apr 30;80(3). pii: 18m12371. doi: 10.4088/JCP.18m12371.

Diese Seite wurde am 02.03.2026 zuletzt aktualisiert.